Mississippi University for Women

ATHENA COMMONS
MSN Research Projects

MSN Research

8-2020

Utilization Of Genetic Screening Practices By Primary Care
Providers For Individuals With Increased Risks For Alzheimer’S
Disease
Cindy R. Quinn
Mallory Stockstill
Lucy Barnes
Jalisha Brown
Angela Reeves

Follow this and additional works at: https://athenacommons.muw.edu/msn-projects
Part of the Nursing Commons

Recommended Citation
Quinn, Cindy R.; Stockstill, Mallory; Barnes, Lucy; Brown, Jalisha; and Reeves, Angela, "Utilization Of
Genetic Screening Practices By Primary Care Providers For Individuals With Increased Risks For
Alzheimer’S Disease" (2020). MSN Research Projects. 268.
https://athenacommons.muw.edu/msn-projects/268

This Thesis is brought to you for free and open access by the MSN Research at ATHENA COMMONS. It has been
accepted for inclusion in MSN Research Projects by an authorized administrator of ATHENA COMMONS. For more
information, please contact acpowers@muw.edu.

Utilization of Genetic Screening Practices by Primary Care Providers for
Individuals with Increased Risks for Alzheimer’s Disease

Cindy Renee’ Quinn
Mallory Stockstill
Lucy Barnes
Jalisha Brown
Angela Reeves

Clinical Research Project
Submitted in Partial Fulfillment of the Requirements for the
Degree of Master of Science and Nursing, College of Nursing
and Health Sciences
Mississippi University for Women
COLUMBUS, MISSISSIPPI
August 2020
i

Graduate Committee Approval
The Graduate Committee of Cindy Renee’ Quinn, Mallory Stockstill, Lucy Barnes,
Jalisha Brown, and Angela Reeves
hereby approves this research project as meeting partial fulfillment of the requirements
for the Degree of Master of Science in Nursing.

Date__________________________ Approved_________________________________
Committee Chair

Approved_________________________________
Committee Member

Approved_________________________________

Committee Member

Approved______________________________
Director of Graduate Studies

ii

Copyright © 2020 Cindy Renee’ Quinn, Mallory Stockstill, Lucy Barnes, Jalisha Brown,
and Angela Reeves
All rights reserved. No part of this work may be reproduced, stored in a retrieval system, or
transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or
otherwise, without the authors' prior written permission.
iii

Dedication
This research is dedicated to GOD, my loving husband Antione,my beautiful daughter
Bayleigh and my family. Without you'll, there would be no me. God, you have heard my
cries and prayers, although a fall short of your glory each and everyday, you continue to
pick up and put me back on the right path. To my husband Antione, thank you for your
unconditional love, sacrifices, and words of encouragement. To Bayleigh, thank you for
being the light on my darkest days as well giving me the motivation to strive for greater. I
hope that someday you will follow in my footsteps. Family, thank you for your endless
support throughout this past year. This has been one of the most challenging, yet
rewarding years of my life. We did it!!

With Love, Jalisha Brown

This research is dedicated to my loving husband William, and my children Paden, Tyler,
and Raelyn. William without you I would not be where I am today. Words cannot
properly convey how much I owe you for the love and support you have shown me over
the last year. Paden, Tyler, and Raelyn never give up on your dreams and no matter what
life throws at you while you are pursuing those dreams, take one minute, one hour and
one day at a time. There were many times during the last year, I wanted to give up, but I
knew that I could never look into each of your eyes and say I gave up. Your smiling faces
gave me the motivation to keep going, and instead of overwhelming myself of what could
happen. I began to take one minute, one hour and one day at a time.

Love Always, Lucy Barnes

iv

This research project is dedicated to my family. First I want to thank my dad for
pushing me and always trying to make me a better person. Without you, I would not be
here. Thank you for never giving up. I also want to thank my children, Kellye and Justin
for loving me unconditionally and being my biggest cheerleaders. I love you both beyond
words. Knowing that you are proud of me makes it all worthwhile. I want to thank
Keisha for being my mentor and my go to person. I value your friendship more than you
know. Last, I want to thank Randy for putting up with all of the complaining and late
night assignments and study sessions. All of your encouragement and motivation kept me
going. I can't thank you all enough. My love and gratitude will never be repayment
enough. I love you all.
Love you always and forever, Angela Reeves

This research project is dedicated to my supportive husband, Conrad, and my loving
family. There is no way I would have been able to succeed on this journey without your
constant support and encouragement. You held my hand and pushed me forward when I
wanted to give up. You reminded me that I am a child of God and to trust in His purpose
and provision when my soul was weary. You celebrated with me through all of my
achievements on this endeavor. I would not have triumphed in this program without your
guidance, love, and encouragement. Words cannot accurately convey how grateful I am
to each of you.
With love, Mallory Stockstill

v
I dedicate this research project to my family. My husband Stacy, who has been
my number one supporter throughout this process. I could not have made it this far
without your love, support, and sacrifice. To my children and grandchildren, thank you
for being my cheerleaders, voices of encouragement, and motivation to persevere. I look
forward to making up all time that was lost while I chased this dream.
Love you all bunches, Cindy Renee’ Quinn

vi
ACKNOWLEDGMENTS
We would like to sincerely offer our thanks and gratitude to the faculty at the Mississippi
University of Women for allowing us the opportunity to work on this project. We have
endured this year of adversity and struggles with not only academic hurdles but with the
extra burden of a worldwide pandemic. We have persevered together and prevailed.
When others were shutting down, we were allowed to keep going. We thank you for that.
We would also like to acknowledge our Clinical Advisor, Dr. Carey McCarter. She has
mentored us from the very first advisor meeting. She has been available for the numerous
questions and complaints that have come from each of us. She has been one of our
biggest advocates throughout this process. We feel that from this day forward, we will
not only refer to you as a colleague but also as a friend.
Thank you,
Mallory Stockstill
Angela Reeves
Cindy Renee Quinn
Jalisha Brown
Lucy Barnes

vii

Utilization of Genetic Screening by Primary Care Providers for Individuals with
Increased Risks for Alzheimer’s Disease

Cindy Renee’ Quinn, RN, BSN
Mallory Stockstill, RN, BSN
Lucy Barnes, RN, BSN
Jalisha Brown, RN, BSN
Angela Reeves, RN, BSN
Supervising Professor: Carey McCarter, DNP, FNP-BC

Abstract
The purpose of this study was to determine if health care providers in the primary
care setting were identifying individuals with increased risks for Alzheimer’s disease and
if the utilization of genetic screening related to the disease was being offered to those
individuals. Extensive research into the genetic etiology of Alzheimer's disease has
proven that some genetic factors are causative and increase a person's risk of developing
the disease. The need for further comprehensive assessments for those with increased
risk of developing Alzheimer’s disease, such as genetic testing, is imperative in
identifying the disease-causing gene mutations associated with the disease. These risk
factors include increased age, family history, diabetes, hypertension, obesity, smoking,
depression, cognitive inactivity, physical inactivity, low education, and specific genetic
markers (APOE-e4). Focusing efforts in the primary care setting on identifying patients
who are at increased risk of developing the disease prior to the clinical onset allows for
the utilization of genetic screening. Identifying cognitively healthy individuals ages 5075, who are at increased risk of developing Alzheimer's disease-related to their age or
genetic variations in genes, will aid providers with diagnosis and clarification of risk for
those individuals and their families. The current study addressed these issues with an
emphasis on health promotion which has the potential of long term benefits of extending
viii

longevity, enhancing the quality of life, and reducing health care cost.
Research was conducted to determine if genetic screening was being utilized in
the primary care setting for individuals who are at increased risk for developing
Alzheimer's disease. This was done by utilization of a quantitative survey. Strict caution
was taken once approval was granted by the Institutional Review Board at Mississippi
University for Women, this was to ensure participant privacy and anonymity as data was
collected. The researchers provided questions in the form of a survey utilizing
SurveyMonkey, Inc. which included demographic data, the determination of provider
assessments, the evidence of genetic screening being offered, the cognitive assessments
used, the reason genetic screening is not utilized, and the follow-up care provided for
those who choose genetic screening. The study had 20 respondents in this sample, which
was also considered a limitation in the research. Based on this sample of respondents
and upon completion of the data, the study determined that genetic testing was not being
utilized by primary care providers in the state of Mississippi for individuals with
increased risk for developing Alzheimer’s Disease.
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CHAPTER 1
Introduction
The purpose of this study was to determine if health care providers in the primary
care setting were identifying individuals with increased risks for the disease, and to
determine if the utilization of genetic screening related to Alzheimer's disease was being
offered to those individuals. Extensive research into the genetic etiology of Alzheimer's
disease has proven that some genetic factors are causative and increase a person's risk of
developing the disease. The need for further comprehensive assessments for individuals
with increased risks of developing Alzheimer’s disease, such as genetic testing, is
imperative in identifying the disease-causing gene mutations associated with the disease.
These risk factors include increased age, family history, diabetes, hypertension, obesity,
smoking, depression, cognitive inactivity, physical inactivity, low education, and specific
genetic markers (APOE-e4). Focusing efforts in the primary care setting on identifying
patients who are at increased risk of developing the disease prior to the clinical onset
allows for the utilization of genetic screening. Identifying cognitively healthy individuals
ages 50-75, who are at increased risk of developing Alzheimer's disease related to their
age or genetic variations in genes, aids providers in diagnosis and clarification of risk for
those individuals and their families. The current study addressed these issues with an
emphasis on health promotion that has the potential of long term benefits of extending
longevity, enhancing the quality of life, and reducing health care cost.

Alzheimer’s disease is a significant health problem across the United States.
There is no standardization in the screening protocol for dementia and its progression.
Alzheimer’s disease and other types of dementia do not limit themselves to one particular
1
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population or socio-economic group. The disease does not discriminate among culture or
ethnicity. Alzheimer’s disease is an irreversible, progressive brain disorder that slowly
destroys memory and thinking skills and, eventually, the ability to carry out the simplest
tasks (NIA, 2017). Alzheimer’s is ultimately ta fatal form of dementia. It is the sixth
leading cause of death in the United States, accounting for almost 4% of all deaths in
2014 (CDC, 2017). The number of Alzheimer's deaths has increased because of the
growing population of older adults. The death rate for Alzheimer’s disease increased
55% from 1999 to 2014. In 2014, over 93,500 deaths across all 50 states and the District
of Columbia occurred due to Alzheimer's disease. Deaths attributed to Alzheimer's
disease increased among adults 75 years or older. It is estimated that by 2050, 16 million
people will be diagnosed with Alzheimer's Disease (CDC, 2017).
In 1906, Dr. Alois Alzheimer noticed changes in the brain tissue of a woman who
has died from an unusual mental illness. Her symptoms included memory loss, language
problems, and unpredictable behavior. After the patient’s death Dr. Alzheimer examined
her brain and found a multitude of abnormal clumps (now referred to as amyloid
plaques)and tangled bundles of fibers (now known as neurofibrillary, or tau tangles). The
complex disease he discovered became known as Alzheimer’s disease. Dr. Alzheimer
concluded that given the complexity of the disease, it was unlikely that one drug or single

specific intervention would successfully treat the problem. Current treatments focus on
the management of disease progression and helping people maintain mental function,
manage behavioral symptoms, and slowing the progression of specific problems, such as
memory loss. Researchers hope to develop therapies targeting specific genetic,
3
molecular, and cellular mechanisms so that the actual underlying cause of the disease can
be stopped or prevented (NIA, 2017). Research has proven that changes in the brain
related to the disease process can be present years before symptoms appear. Evidence
targets other disease processes that may contribute to Alzheimer's disease, such as heart
disease, high blood pressure, and high cholesterol. Early detection of genetic markers
that are known to be present in Alzheimer's disease could provide the opportunity to
make changes that could delay or stop the disease progression. Modifiable risk factors
such as exercise, diet, and cognitive challenges have been shown to slow or even possibly
arrest the disease process (CDC, 2017).
Statement of the Problem

Alzheimer's disease is a progressive neurological illness that continues to affect
thousands of individuals annually. Scientists have identified three genetic markers with
rare variations related to Alzheimer's disease, along with other genetic markers that are
known to suggest increased risk; however, these do not guarantee that a person will
develop the disease. Investigators worldwide are working to identify additional genes
responsible for causing Alzheimer’s disease. As more effective treatment becomes
available, genetic profiling may become a valuable risk assessment tool for broader use.

Genetic screening for APOE-e4, the most influential risk gene, is included in some
clinical trials to identify participants at high risk for the disease (Alzheimer's Association,
2019). Risk factors for the disease include not only age and family history, but also

diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical
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inactivity, and low education. These factors are critical components in identifying the
disease-causing gene mutations associated with Alzheimer's disease. The problem of
interest in this study was based on whether or not genetic screening was utilized in the
primary care setting for patients with an increased risk of Alzheimer's disease. As the
population ages, the prevalence of the disease will continue to rise. The cost of
treatment, long-term care, and caregiver's health maintenance will also continue to rise.
This cost could potentially put additional strain on the health care system.

It was predicted that providers in the primary care setting would be confronted
with barriers to genetic screening. The barriers included: cost to the patient; insurance
coverage; education of the population regarding the effects of the disease; lack of time to
educate the patient in the clinical setting; and lack of staff education and training related
to the disease. Review of literature revealed numerous studies that demonstrated the
early screening of patients with a family history, along with other risk factors such as
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical
inactivity, low education, and specific genetic markers (APOE-e4) could promote

lifestyle changes that could alter the progression of the disease. Early intervention could
be the key to controlling this disease and future research.
Statement of the Purpose
The purpose of this study was to determine if genetic screening was being utilized
in the primary care setting for individuals who were at increased risk for developing
Alzheimer's disease. The risk factors which include increased age, family history,
5
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical
inactivity, low education, specific genetic markers (APOE-e4) that predispose individuals
to Alzheimer’s disease. These risk factors can appropriately be identified in the primary
care setting. The present study allowed insight into the utilization of genetic screening to
identify at-risk individuals, and if genetic screening concerning Alzheimer's disease was
provided in the primary care setting. Early detection of risk factors related to
Alzheimer’s disease would provide the opportunity for patients and providers to reduce
the prevalence and complications of this disease. Early identification of individuals at
risk for Alzheimer’s disease, coupled with genetic screening, would decrease the burden
of effects on concerned individuals and their family members. Continued education
related to genetic screening and Alzheimer’s disease is needed for both health care
providers and individuals with increased risks of the illness like the following: age,
family history, diabetes, hypertension, obesity, smoking, depression, cognitive inactivity,
low education, and specific genetic markers (APOE-e4) to stay aware of current
treatments and resources available. Research related to genetic testing and Alzheimer’s

disease will help to develop an open dialogue among providers and increase awareness of
the disease and the availability of genetic screening.
Significance of the Study
The significance of this study has proved to be useful to primary care providers, as well
as neurologists and psychiatric-mental health professionals who diagnose, treat, and
manage patients with Alzheimer's disease. While there are no preventive strategies or
cures for Alzheimer's disease currently, timely diagnosis is essential for effective
6
management. People are living longer, but the quality of life has diminished significantly
in the 21st century. Early detection allows patients and their families the option to modify
risk factors related to diabetes, hypertension, obesity, smoking, depression, cognitive
inactivity, physical inactivity, low education, and specific genetic markers (APOE-e4).
This also allows the patient to receive symptomatic treatment to support lifestyle
modifications, such as exercise, diet, and cognitive exercises. Early detection also
provides the patient the opportunity to make plans for the future. Extensive research into
the genetic etiology of Alzheimer's disease has proven that some genetic factors are
causative and increase a person's risk for the disease. The need for further
comprehensive geriatric assessments, such as genetic testing, is a critical component in
identifying the disease-causing gene mutation associated with Alzheimer's disease.
Focusing efforts in the primary care setting on identifying patients who are at increased
risk of developing the disease prior to the clinical onset allows for the utilization of
genetic screening. Identifying cognitively healthy individuals ages 50-75, who are at
high risk for developing Alzheimer's disease related to their age or genetic variations in

genes, will aid providers with diagnosis and clarification of risk for those individuals and
their families.
Conceptual Framework
Nola Pender's Health Promotion Model was chosen as the theoretical model for
the current research project because Nola Pender’s model promotes prevention as a
means of total health and wellness. She developed her Health Promotion Model, often
abbreviated HPM, after seeing professionals intervene once a patient developed an acute
7
or chronic illness. She became convinced that the prevention of problems could improve
a patient’s quality of life and the promotion of healthy lifestyles could save health care
dollars. Nola Pender's framework focuses on the positive aspects of health. The initial
version of the model appeared in 1982, and a revision of the model in 1996 was based on
changing theoretical perspectives and empirical findings (Petiprin, 2016). Nola Pender
incorporated psychological educational nursing concepts, and theories to formulate the
Health Promotion Model. Pender's model stated that people have the capacity for
reflective self-awareness, including assessment of their competencies. Self-awareness
would motivate a positive change and create a desire for the individual to change his
habits once he is aware of how negative behavior would impact his health. Pender's
model emphasizes the conceptual propositions that barriers place constraints on the
commitment to action. These barriers would include the cost of healthier food choices,
association with individuals that use tobacco products and exposure to second-hand
smoke, or the lack of wellness visits at the appropriate intervals. For example, an
individual who is a smoker and obese is educated on risk factors for Alzheimer's disease.

With the knowledge provided that smoking and poor food choices increase the
individual's risk in the development and progression of the disease, it could be inferred
that the individual would elect to discontinue these activities as an effort to promote his
health. Pender's model is based on the concept that education will increase a patient's
desire to make healthier lifestyle choices and become healthier in body and mind. Once
the benefits of making lifestyle changes are perceived and barriers removed, the
individual would then commit to a plan of action to achieve a health-promoting lifestyle.
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Pender's model concerning Alzheimer's testing in the primary care setting,
emphasizes that health promotion would allow the choice of wellness rather than
aggressive disease. Every patient with increased risk factors, should have the opportunity
to choose genetic testing. Genetic testing would enable each patient to have further
education on the disease. Genetic counseling, support groups, and online training would
be considered part of genetic testing according to Pender's concept.
Pender's Model would allow everyone to individually determine if socio-cultural,
economic, or political conditions could affect their health status. Health care providers
must be educated in the benefits of early detection so that the general public can be
knowledgeably informed. Primary care clinics could also raise awareness about healthy
behaviors for the general public. Raising awareness would include health fairs,
newsletters, and mass media communications to promote community involvement and
knowledge of the benefits of genetic testing and Alzheimer's prevention. The current
study utilized a survey that was sent via email and social media sites that include primary
care providers. The survey was to determine if primary care providers were offering the

option of genetic screening to patients with an increased risk of Alzheimer's disease. The
Health Promotion Model was selected to guide this research because of the model's focus
on wellness-related health promotion.
Research Questions
Two research questions were developed to guide data collection regarding the utilization
of genetic screening by primary care providers for individuals with increased risks for
Alzheimer’s disease.
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1. Are patients who are at increased risk of developing Alzheimer's disease being
identified by primary care providers in the primary care setting?
2.

Are primary care providers utilizing genetic screening for patients who are at
increased risk of developing Alzheimer's disease?

Definition of Terms
For this study, several terms were defined as they apply to this study. The theoretical and
operational definitions follow, respectively.
Patient
Theoretical. Tabor’s defines a patient as one who receives medical care
Operational. This study defines a patient as a person that is at an increased risk of
developing Alzheimer's disease.

Increased Risk Factors

Theoretical. Tabors define risk factors as an environmental, chemical,
psychological, physiological, or genetic element that predisposes someone to the
development of the disease.

Operational. This study defines increased risk factors of Alzheimer’s disease
based on guidelines determined by the Alzheimer’s Association. These increased
risk factors include not only age and family history, but also diabetes,
hypertension, obesity, smoking, depression, cognitive inactivity, physical
inactivity, low education, and specific genetic markers (APOE-e4). The study
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identifies these factors as placing patients at increased risk of developing
Alzheimer's disease.

Alzheimer’s Disease
Theoretical. Tabor’s defines Alzheimer’s disease as a chronic, progressive,
degenerative cognitive disorder that causes deterioration in thinking and everyday
functioning among older adults.
Operational. This study defines Alzheimer's disease as a chronic, cognitive
disease that causes debilitating dysfunction to the patient and their family.
Primary care providers

Theoretical. Tabor’s defines the primary care provider as a professional who
gives health care services or an institution that supervises the rendering of
such

services.

Operational. This study defines the primary care provider as a Doctor of
Medicine, Doctor of Osteopathic Medicine, physician’s assistant, or a nurse
practitioner in a clinical setting who provides health care to patients targeted in
this study.

Primary care setting
Theoretical. Medicine.Net defines a Primary health care setting as a patient's
leading source/setting for regular medical care, ideally providing continuity and
integration of health care services.
11
Operational. This study defines primary health care as the setting in which the
patient shares concerns about the need for genetic screening for Alzheimer’s
disease.

Genetic Screening
Theoretical. The National Cancer Institute defines genetic screening as testing
designed to identify individuals in a given population who are at higher risk of
having or developing a particular disorder or carrying a gene for a specific
disease.

Operational. This study defines genetic screening as a blood test used to help
providers in the primary care setting in Mississippi identify individuals who are at
increased risk of developing Alzheimer's disease.

Assumptions
For this study, the following assumptions were made.
1. The researchers assumed health care providers, in the primary care setting
(physicians, nurse practitioners, and physician assistants), were to be adequate
and equivalent educational and professional providers that would be practicing
with a valid, unencumbered license and within a proficient or expert competency
level.
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2. The researchers assumed that the sample population of primary care providers
assessed a uniform number of individuals that could be considered at risk for
Alzheimer’s disease and were familiar with risk factors for Alzheimer's disease.

3. The researchers assumed that the information obtained from this study could be
obtained by a survey provided through Survey Monkey, a reliable web-based
survey building company.

Summary of Background
The explanation for the current study was discussed in this chapter. Researchers
sought to determine if providers in the primary care setting were identifying individuals/
patients with increased risk of developing Alzheimer's Disease. These individuals were

defined as those with risk factors such as age and family history, diabetes, hypertension,
obesity, smoking, depression, cognitive inactivity, physical inactivity, and low education.
All of these are crucial elements in identifying the disease-causing gene mutations
associated with Alzheimer's disease. The researchers also sought to determine if primary
care providers were offering and utilizing genetic screening for those individuals/patients
that were identified with positive risk factors for developing Alzheimer’s. After
reviewing the literature associated with this ongoing health crisis, it was revealed by
numerous studies that early testing of patients with a family history or other
predispositions to the disease, such as hypertension, diabetes, obesity, smoking,
depression, cognitive inactivity, physical inactivity, low education, and specific genetic
markers (APOE-e4), could invoke lifestyle changes, such as diet, physical exercise, and
cognitive exercise could modify the progression of the disease. It was predicted that early
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intervention would be a substantial component in controlling this disease. By directing
energy toward identifying patients in primary care who are at high risk for developing
Alzheimer's before the clinical onset of the disease, preferably cognitively healthy
individuals ages 50-75 with positive risk factors, then the option of genetic testing can be
pursued. These genetic variations can later be further identified and aid providers with
definitive diagnosis and interpretation of risk for those individuals and their families.
Sharing the information collected from this study with primary care providers and the
public could prove to be the key to early detection and prevention of this disease.

CHAPTER II
Literature Review
Identification of individuals who are at risk of developing Alzheimer's disease is of
utmost importance. Early diagnosis allows for tailored counseling and care of patients
and their caregivers. Providing symptomatic treatment and support also aids patients and
family members in planning for the future. The purpose of this study was to determine if
health care providers in the primary care setting were identifying individuals with
increased risks for the disease and if genetic screening related to Alzheimer’s disease is
being utilized in the primary care setting. Extensive research into the genetic etiology of
Alzheimer’s disease has proven that some genetic factors are causative and increase a
person’s risk of developing the disease. The need for further comprehensive assessments,

such as genetic testing, for those with increased risk factors such as not only age and
family history, but also diabetes, hypertension, obesity, smoking, depression, cognitive
inactivity, physical inactivity, low education, and specific genetic markers (APOE-e4) is
a critical component in identifying the disease-causing gene mutations associated with
Alzheimer's. By focusing efforts identifying patients in the primary care setting who are
at increased risk for developing the disease before clinical onset, opens the door for
genetic testing. Determining cognitively healthy individuals ages 50-75, who are at
increased risk of developing Alzheimer's disease-related to their age or genetic variations
in genes, will aid providers with diagnosis and clarification of risk for those individuals
and their families. This chapter introduces the theoretical framework utilized in this
research, and also presents a review of research as a reference to the current study.
14
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Theoretical Framework
Theories are an essential guide to the nursing profession. Nursing theories impact
the way providers care for patients and maintain the integrity of the profession. Nola
Pender, a pioneer in the nursing profession, made a significant contribution to the nursing
profession as the founder of the Health Promotion Model in 1982. Pender’s theory/
model is used universally for research, education, and practice. Through revisions and
evidenced-based practice, this theory has evolved throughout the years to become the
basis for preventive health measures and the critical function of nurses in helping patients
prevent illness by promoting well-being and healthy lifestyles. Health promotion is
essential for many reasons. The rising costs of healthcare and improving patient

outcomes have become of increasing interest not only to health care workers but also to
the general public. The health promotion model focuses on helping individuals achieve
higher levels of well-being by providing positive resources to help patients make
behavior-specific changes. Research has proven with the implementation of the health
promotion model; patients can prevent illness through their behavior. In this paper,
Pender's Health Promotion Theory is thoroughly defined, and a thorough critique of
research studies utilizing this model will indicate the usefulness of the theory in various
populations and disease processes.
Nola Pender defines health as not just being free of disease but includes measures
taken to promote good health, the individual’s self-perception, and lifestyle. Pender's
definition of health is the actualization of inherent and acquired human potential through
goal-directed behavior, competent self-care, and satisfying relationship with others while
16
adjustments are made as needed to maintain structural integrity and harmony with
relevant environments (Pender, Murdaugh, & Parsons, 2011). Her definition of health is
the basis of the Health Promotion Model. Pender’s theory/ model offers a holistic view
of the patient, assessing the patient’s history and self-perception to allow providers to
intervene and form a plan of care accordingly. The theory is meant to serve as a guide to
explore complex biopsychosocial processes and motivate individuals to engage in
behavior that is directed toward the promotion of health (Pender, Murdaugh, & Parsons,
2011). This guide allows the health promotion theory to be applied to all populations and
makes this theory an excellent guide for the current study.

Nurse practitioners and primary care providers play key roles in developing and
providing resources for innovative prevention and health promotion programs. The
primary emphasis on health promotion has the potential long-term benefits of extending
longevity, enhancing the quality of life, and reducing health care costs (Pender & Pender,
1980). The current study addressed these issues, with a focus on determining if genetic
screening is being provided in the primary care setting for those with increased risk of
Alzheimer's disease. Adding this focus in the primary care setting can allow for early
detection and identification of those with increased risks of developing Alzheimer's.
Identification of at-risk individuals provides for timely diagnosis and the availability of
genetic testing. Early detection can allow both patients and their families to receive
effective management, treatment, and support. It can also provide those with increased
risks of Alzheimer's disease the opportunity to plan for the future. Utilization of the
health promotion model will promote wellness through the use of genetic screening for
17
Alzheimer's disease, allowing individuals the choice of wellness by providing genetic
counseling, support groups, and other resources designated for this disease.
Review of Literature
Brodaty, Connors, Loy, Teixeira-Pinto, Stocks, Gunn, Mate, and Pond (2016.) performed
a cluster-randomized trial that examined the effectiveness of a peer-led intervention for
general practitioners to improve the assessment and management of dementia. The study
compared the General Practitioner Assessment of Cognition (GPCOG) and the MiniMental State Examination (MMSE) in terms of their ability to detect dementia in primary
care. Identifying individuals at risk for developing dementia and Alzheimer’s is often

overlooked in the primary care setting. While a timely diagnosis of the disease is vital
for effective management, treatment, and support for patients and their families, the
pressure of time constraints in the primary care setting often makes it difficult to assess
cognitive decline in this setting adequately. The MMSE, one of the most widely used
instruments to test for cognitive deficits, takes approximately ten minutes to perform and
makes it impractical to use in the primary care setting. While the GPCOG, also a tool for
cognitive impairment, was developed to assess cognitive deficits rapidly and only takes
4-6 minutes to perform. Data on the effectiveness of this screening tool in the primary
care setting is limited. In this study, a sample of 2,028 patients was used to compare the
GPCOG and the MMSE in their terms of ability to detect cognitive deficits such as
dementia and Alzheimer’s disease within the primary care setting. The Cambridge
Examination for Mental Disorders of the Elderly Cognitive Scale-Revised (CAMCOG)
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was used as an index for likely dementia. No theoretical framework was identified for
this study.
Brodaty, et al. hypothesized that the GPCOG would perform as well as the
MMSE to detect deficits in cognitive function or dementia. The study questioned if the
GPCOG could be utilized in the primary care setting, in place of the time-consuming
MMSE with comparable results. The sample included elderly adults from the primary
care population aged 75 years or older that had visited their general practitioner in the last
24 months. Those with neurological disease, psychotic symptoms, developmental
disability, substance abuse, progressive malignancy, or an illness that would prevent the

patient from completing the study were excluded. Written informed consent was
obtained from all patients, general practitioners, and informants to participate. Each
participant completed a detailed cognitive screen by trained research nurses, and each
screening was achieved by utilizing a home visit or a visit to the general practitioner's
office. Four instruments were utilized in the baseline cognitive screen. These four
instruments included the GPCOG, the MMSE, Geriatric Depression Scale (GDS), and the
CAMCOG. The CAMCOG, which uses diagnostic criteria such as memory, language,
attention, perception, praxis, and executive function to test each patient's cognitive
function. The CAMCOG has 59 items covering seven domains and includes the MMSE
as a subtest. The highest possible score on the CAMCOG is 104, with anything <79 is
indicative of dementia. This instrument was administered first. The GPOG and GDS
followed. The GDS was used to determine if depression influenced the participant's
performance of the other tools being used in the study. A 15 item measure was utilized
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on this scale. A score >6 indicative of possible depression, with >10 indicating definite
depression. The GPCOG consists of two sections; the first section is the patient cognitive
examination that is scored 0-9. A score of <5 indicates cognitive impairment, and a score
of >8 indicates impairment is unlikely. The second section is an interview with the
patient's informant. This section is only given when the patient scores between 5-8 on
the first section. The interview section is scored 0-6. A higher score is indicative of
better cognition and function. These two scores are totaled to produce the GPCOG-total,
a measure of 15. A cut-point score of 10/11 is likely indicative of cognitive impairment.
Of the 2,028 participants, 1,717 (84.7%) completed all three relevant instruments

(CAMCOG, GPCOG, MMSE) administered in the study. Of the 1,717 participants, 126
(7.3%) met the criteria for likely dementia by the CAMCOG screening. The MMSE and
GPCOG score on these participants were lower than the participants were older than
those who did not meet these criteria. An informant interview for the GPCOG was
required by 409 of the 1,717 participants. Analysis of the study's results was assisted by
McNemar's test to compare sensitivity, specificity, and misclassification rates of the
GPCOG and the MMSE. Receiver operating curves (ROC) and Delong's non-parametric
test was used to allow comparison of the GPCOG and MMSE, including the area under
the curve (AUC). Using published cut-points (10/11 for the GCPOG, and 23/24 for the
MMSE) the GCPOG had greater sensitivity than the MMSE in detection of dementia
(0.79 vs. 0.51, p < 0.01), though lower specificity (0.92 vs. 0.97, P < 0.01). The results
were consistent despite the GPCOG's shorter administration time, indicating the GPCOG
performs similarly to the MMSE in detecting likely dementia. The GPCOG and MMSE
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showed similar sensitivities and specificities across the range of test scores using the
ROC analysis. These results suggest possible advantages of using the GPCOG as a triage
test to identify the increased risk of dementia and Alzheimer's.
Despite limitations within the study, it confirms the GPCOG performs similarly to the
MMSE. These results make the study very relevant to the current research study for
several reasons. Given the MMSE’s administration time is often impractical in the
primary care setting, the findings of the GPCOG’s performance provides a viable
alternative for dementia screening. Time investment is a significant limitation in
providing cognitive screening to the elderly. Requiring less time to administer, utilizing

the GPCOG in the primary care setting would increase the likelihood of dementia
screening being provided. Positive screening would indicate the need for further in-depth
assessments by the primary care provider or a referral for further evaluation or
management.
The current study will help determine if individuals at increased risk of
Alzheimer's disease are being identified and if the utilization of genetic testing is being
provided in the primary care setting for individuals with increased risk for Alzheimer’s
disease. Baseline assessments of dementia and cognitive impairment are critical for
further genetic testing of individuals at risk. The ability to provide improved risk
assessments followed up with genetic risk testing will aid in diagnosis and potentially
clarify risks for the patient and family members affected by the disease. Nola Pender's
Health Promotion Model will help guide the current study based on the theory's concept
and emphasis on health promotion. This model can be a crucial influence for primary
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care providers in utilizing genetic testing for individuals and the family members of those
who are at increased risk for Alzheimer’s disease.
Evenson, Hoyme, Haugen-Rogers, Larson, and Puumala conducted and reported
results of their study, in which they sought to learn about the perceptions of outpatient
internal medicine physicians and their patients regarding genetic testing, to help to inform
the development of the integration of genetic testing into primary care. As part of a
program that will progressively integrate genetic testing into primary care, this study's
results will serve as baseline data about these patients and physicians, which will be
referred to in future research studies. Genetic testing is becoming a part of primary care,

and the perceptions of both providers and patients are essential to program design and
development. Evenson et al. did not indicate a theoretical foundation for their research
study.
While Evenson et al. did not clearly state their research questions or hypotheses in
the article, the purpose of the research focused on learning more about perceptions of
internal medicine physicians and their patients regarding issues related to genetic testing
in primary care settings. Questions motivating the research study included: What is the
knowledge level of internal medicine physicians about genetic testing in primary care;
what is the confidence level of these providers about communication with their patients
about genetic testing; how do internal medicine physicians feel about the roles and uses
of genetic counselors in primary care; what is the knowledge level of patients of internal
medicine physicians about genetic testing; what are patients’ perceptions of the
usefulness of genetic testing; what are patients' concerns about genetic testing?
22
These same questions were utilized in their survey to clarify the scope of the
research. This research study took place at 13 primary health clinics in three Midwestern
states: North Dakota, South Dakota, and Minnesota (Evenson et al., 2016). Due to this
study being funded by the University of South Dakota-Sanford School of Medicine, the
clinics chosen were part of a program they used to integrate genetic testing into primary
care. The physicians and patients surveyed came from these 13 clinics. The researchers
prepared surveys to allow them to obtain relevant information. Content experts first
approved surveys. After patients visited their internal medicine physicians at one of these
13 clinics, they were given the survey to take home, complete, and send back. For patient

surveys, 1,000 were distributed. Only 14% of the patients responded. All 62 of the
internal medicine physicians at these 13 clinics received web-based questionnaires. A
total of 42% (N = 26) of the physicians responded. The researchers gathered descriptive
data about the respondents. Data reported that the patients included age, education, sex,
race, marital status, location, and income. For the physicians, descriptive data included
sex, age, years in practice as a physician, and whether or not they had ordered genetic
testing in the past six months or ever. Patient surveys consisted of statements about their
knowledge of genetic testing, their openness to it, their concerns about it, and their
perceptions of its value or benefit. Physician surveys consisted of statements related to
knowledge of genetic testing and genetic counselors in primary care. Perceptions of its
relevance and the physician's level of confidence in communicating about genetic testing
with patients were also included. Case studies were also part of the physician
questionnaires.
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Patients reported knowledge, interest, and openness to genetic testing in primary
care, as well as concerns about privacy; many patients would prefer to hear about their
results from a genetic counselor than their physician. Physicians expressed immense
knowledge of genetic testing but lower levels of confidence about communicating with
patients about it. Implications of this research contribute to the need for ongoing research
as genetic testing becomes more integrated with primary care; the authors encouraged
further research.
Caselli, Langbaum, Marchant, Lindor, Hunt, Henslen, Dueck, and Robert
conducted a study to determine perceptions from a public viewpoint on genetic testing for

Alzheimer's disease. They sought to answer questions based on the desire for genetic
testing, the reaction to results once testing was concluded, and the knowledge of those
results concerning the disease process. Alzheimer's disease is very prevalent, and it is
believed to increase the susceptibility of inheritance if positive for the apolipoprotein E
(APOE) genotype. Carrying this genetic makeup poses the most considerable risk of the
development of the disease. However, with no known cure for this disease, providers
have difficulty with the management of pre-symptomatic testing of Alzheimer's and the
proper way to disclose this information to patients. While direct-to- consumer marketing
can be a positive resource to some of the population, screening, counseling, and followup with consumers is unlikely to occur once purchase is made. However, if genetic
testing for Alzheimer's disease was provided in a primary care clinic with a trusted health
care provider on individuals who are likely to seek testing, then screening, counseling,
and follow-up visits could be scheduled and carried out. The researchers designed a
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questionnaire to assess the following: "the desire for preclinical testing in the absence of
effective interventions, the possible reactions to such information, and how well the
results of such testing would be understood." The researchers developed a questionnaire
containing a series of yes/no and multiple-choice questions. Portions of this
questionnaire determined the patient's demographics. This included age, sex, race,
education, a first degree relative with Alzheimer's disease and other family affected,
caregiver experience, and if the individual resided in an area where they were not raised.
The questionnaire proceeded to ask questions about disease perception. It
determined the percentage of individuals who found genetic testing to be essential and

separated those who were only in agreement when it was covered by insurance. It
determined the individuals' support system, and it revealed how those who hypothetically
tested positive would react. These options included: live a healthier life, invest in long
term care insurance, spend all money for pleasure or consider suicide. The survey also
asked two multiple-choice questions to determine the knowledge of the respondent
concerning their potential positive genetic results. The researchers proceeded to post the
survey on the Alzheimer's Prevention Registry website. The survey was available online
with site visitors who registered on the website between November 1, 2012-June 30,
2013. Those registered with the Alzheimer's Prevention Registry must be over the age of
18 and interested in the development of new research for Alzheimer's disease for personal
knowledge development or to be a potential candidate in future research studies related to
Alzheimer's disease. A total of 4,036 surveyors participated in the research study. The
researchers used descriptive statistics that included the evaluation of continuous and
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categorical data. The continuous data were analyzed using unpaired t-tests and univariate
regression and presented using mean +/- standard deviation. The questions on the survey
were defined as the independent variable. The participants were defined as the dependent
variable. The survey included the opinion of genetic testing, isolated those interested in
genetic testing, and determined the reaction of the results from the genetic testing. The
two multiple-choice questions to determine the participants' knowledge of
presymptomatic genetic testing of Alzheimer's disease for each of the previously
mentioned demographic variables were analyzed using this method. Also, the categorical
data were analyzed using chi-square and multivariate analysis and presented using

frequency. This information included the eight demographic variables that were
evaluated using odds ratios and 95% confidence intervals. Once the data was analyzed,
the researchers determined a strong desire for pre-symptomatic genetic testing for
Alzheimer's disease among individuals. Of the participants, the mean age was 45-80,
while the mean education was 12-20 years. Eighty-two-point, one percent of participants
were women, and well over half the respondents reported having a first degree relative
with an Alzheimer's diagnosis. Seventy-eight-point three percent of the surveyors
believed they were at a higher than average risk of developing Alzheimer's disease at
some point in their life. The survey asked participants their most significant disease
related fear, and 82% of participants selected Alzheimer's disease over a heart attack,
stroke, or cancer. With knowledge of no cure for the disease, 70.4% of participants felt
genetic testing being offered was imperative. However, 80.8% of participants would elect
to have presymptomatic genetic testing if insurance coverage was offered, while only
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58.7% would elect for testing with a minimum of $100 out of pocket cost. The
participants were also asked how they would respond to possible positive genetic results.
Of those asked, 90.5% stated they would commit to a healthier lifestyle, which correlated
with the individual's education level. In contrast, 76.3% of individuals would seek to
obtain long term care insurance if they had not already, which correlated with age and
male gender. Of the surveyors, 18.4% responded to these possible results by choosing to
live the rest of their life to the fullest and spend all of their earned money, which
correlated mostly with the racial background of white, non-Hispanic individuals. The
remaining 11.6% stated they would "seriously consider suicide" if they received positive

genetic results that correlated with education. Lastly, the multiple-choice questions were
listed to assess the knowledge of the individuals. The researchers asked about the
outcome of an APOE e4 Alzheimer gene carrier with no current signs and symptoms of
Alzheimer's disease. Of the participants, 86.9% were able to correctly identify that this
carrier was at an increased risk for Alzheimer's disease. Still, it did not currently
determine the existence of the disease in the individual. However, of the participants,
only 32.6% were able to determine the existence or increased risk for diagnosis of
Alzheimer's disease when associated with a positive biomarker test, such as an amyloid
PET scan, and mild cognitive delay. From this study, the researchers determined that
much more education regarding presymptomatic genetic testing for Alzheimer's disease
is needed. The researchers also determined that those who had a positive family history
of Alzheimer's disease were more fearful of the development of the disease themselves
and were more likely to proceed with genetic testing. However, most individuals stated t
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they would be willing to talk with someone, such as a health care provider or family
member if they were to test positive for the APOE genetic marker. The researchers
determined that psychological evaluation and genetic counseling should be ensured
before the information is revealed to individuals who chose to participate in any genetic
testing, especially those that currently are without a cure like Alzheimer's disease. They
also determined that genetic testing can be beneficial for some, such as easing worry in
those who are low risk or allowing those that are of high risk to participate in a healthier
lifestyle as a preventative measure. A recommendation for future research within this
article would be to expound on the compliance of positive lifestyle changes concerning

prognostic testing for this disease. This article supports the student nurse practitioners'
research on The Utilization of Genetic Testing in the Primary Care Setting for Individuals
with Increased Risk of Alzheimer's Disease through determining the interest of the public
population in genetic testing for Alzheimer's disease. It determines the desire for testing
and assesses the public understanding of the testing. With such an increase in direct to
consumer genetic testing offered without any follow-up care, genetic counseling, or
provider recommendations on a disease process that has limited therapeutic options and
no cure, this study supports the idea that this genetic testing should be offered in a
primary care setting where the provider can disclose results and can offer memory
enhancing medications, genetic and psychiatric counseling, and emotional support.
Huang, Huston, and Perri conducted a research study that sought information
regarding the preferences of consumers in the United States regarding predictive genetic
testing for Alzheimer's disease (AD), to help to inform health-care providers,
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policymakers, and developers of genetic testing. In the United States, Alzheimer's
disease is currently the sixth most common cause of death. With the population aging
and the prevalence of Alzheimer’s disease increasing, researchers need to gain
knowledge about the disease and patient’s perceptions and attitudes about genetic testing
(Huang et al., 2014). Specifically, learning how individuals decide on whether or not to
undergo predictive genetic testing for Alzheimer’s disease will help health-care providers
and policymakers. Huang et al. referred to this study as a “rating conjoint study,” based
on Lancaster’s consumer theory. This theory serves as the framework of this study using
conjoint analysis, where an individual appreciates consuming a good that is made up of

various characteristics or attributes (Huang et al., 2014). Huang et al. (2014) stated their
research question for the study clearly. What characteristics of predictive genetic tests
for Alzheimer's disease do consumers in the United States find to be the most important
when deciding whether or not to undergo this predictive testing? Hypotheses were not
articulated in the article. In this study, the three factors that were rated and analyzed were
predictive value, treatment availability, and anonymity.
Through Qualtrics, the researchers distributed an anonymous online survey using
conjoint analysis to a panel from the general population (Huang et al., 2014). The survey
went through three rounds of pre-testing before the final survey phase of the study. The
only inclusion criterion was that respondents had to be adults between the ages of 18 and
64. Twelve scenarios regarding predictive genetic testing for Alzheimer’s disease were
presented to the respondents, who rated the scenarios by answering 17 questions on an
11-point scale. They also answered open-ended questions about what dollar amount they
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would be willing to pay for the genetic testing related to Alzheimer’s disease in each
scenario. The scenarios each contained different aspects of the three variables: predictive
value of the genetic test, treatment availability for Alzheimer’s disease, and anonymity.
Over four days, a total of 295 participants responded online. The researchers collected
these responses (N = 295). Descriptive statistics regarding the respondents indicated that
their mean age was 44; 86% of the respondents were white; 39% held at least a bachelor's
degree; 53% had annual household incomes of $50,000 or less; there were equal numbers
of male and female respondents. Regarding Alzheimer’s disease, in this sample, 15% of

respondents had a family member with the diagnosis of Alzheimer’s disease, and 16%
had served as caregivers for someone with the disease.
Huang et al. analyzed the results of the survey and found that the most important
of the three factors was accuracy, rated to be of top importance by 64% of the
respondents. Treatment availability and anonymity represented 21% and 15% of the
respondents’ preference ratings. The most preferred scenario was a genetic test for
Alzheimer’s disease that would be 100% accurate, with a cure available for Alzheimer’s
disease and anonymous test results. Respondents indicated that they would accept a test
that had 80% accuracy if a cure for the disease was available. Regarding their
willingness to pay for the test, 12.9% indicated that they would not be willing to pay for
any of the scenarios. Of those respondents who did indicate a willingness to pay, they
noted that they would pay $100 for the test in the most preferred situation. All scenarios
with 100% accuracy had the highest willingness-to-pay results, while those scenarios
with as low as 40% accuracy always showed the lower willingness-to-pay results.
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Implications of the study include the importance of certainty of predictive genetic tests to
consumers. The authors suggested future research studies using samples that are more
representative of the general population, as well as future research on consumer
preferences as treatment options and predictive value of genetic testing for Alzheimer’s
disease continue to improve (Huang et al., 2014).
This research identifies the preferences of genetic testing related to Alzheimer's
disease and recognizes the benefits of utilizing this testing in the primary care setting. It
adds to the knowledge base about patients’ perceptions and values regarding genetic

testing. This consumer research study helps give an insight into how patients in the
current study will perceive testing.
Wollam, Weinstein, Saxton, Morrow, Fowler, Suever-Erickson, Roecklein, and
Erickson performed a neuropsychological evaluation and consensus to determine if the
genetic risks of processing multiple risk alleles associated with Alzheimer's disease can
be a predictor of increased risk of late-life cognitive impairment. Alzheimer's disease
(AD), being the most common cause of irreversible dementia, continues to grow in
prevalence and public health impact, according to both the National Institute of Health,
and the National Institute of Aging, and Human Services Department. Research on the
genetic etiology of Alzheimer's disease has provided knowledge of some genetic factors
that are causative and increase the risk of the disease. While family history is a
significant risk factor for Alzheimer's disease, other genetic variants have been identified
as risk factors for cognitive decline. These variants include Brain-Derived Neurotrophic
Factor (BDNF), Catechol-O-Methyltransferase (COMT), and Apolipoprotein E (APOE).
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In this study, with a sample of 95 older adults, a genetic risk score was constructed based
on the accumulation of these genetic alleles/variants. Identification of these variants in
the primary care setting will provide improved significant risk estimates to individuals
based on the presence of one or more susceptibility gene alleles. No theoretical
framework was identified for this study.
Wollam, et al. identified the hypothesis for this study by the prediction that a
higher genetic risk score would correspond to an increased risk of cognitive impairment.
By studying target gene variants (genotypes), candidates with increased genetic risks

allowed for a genetic risk score to be assigned. APOE, which identifies a clear link to
Alzheimer's Disease; BDNF and COMT, which both have essential roles in brain
functions in late adulthood, were targeted to investigate how multiple gene influences can
be aggregated into a single risk profile to predict the prevalence that could predispose
individuals to Alzheimer's Disease. The testing of the combination of these three highrisk genotypes would be predictive of late-life cognitive impairment.
The study utilized data and sampling methods that were collected as part of more
extensive research examining the utility of providing cognitive testing in older adults in
primary care physician (PCP) offices. Risk factors for late-onset Alzheimer' Disease
identified by the Genome-Wide Association Studies (GWAS) were used to guide this
study. The study was conducted in the offices of eleven primary care providers in greater
Pittsburgh and surrounding areas. The parental study included 109 participants that were
recruited based on the criteria of being 65 years or older, no medical chart diagnosis of
dementia, no acute illness, and permanent residence was not a nursing home facility. Of
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the 109 Participants that provided consent through the University of Pittsburgh
Institutional Review Board before beginning the study, five were excluded initially. The
exclusions were related to incorrectly recorded data and allelic frequency differences
between races. Nine additional exclusions were made after the study began, related to
missing genotype information from one or more genes.
Each participant completed a comprehensive neuropsychological test panel
assessing five cognitive domains: memory, executive function, spatial ability, language,
and attention/ psychomotor speed. Three expert neuropsychologists made a

determination of the cognitive status. Cognitive status was classified as normal, mild,
cognitive impairment (MCI), or dementia. These classifications were based on the
University of Pittsburgh Alzheimer's Disease Research Center. With the final diagnosis
taking into account, cognitive test scores, as well as demographics, functional,
behavioral, and medical information. Adjudications were conducted blind to the study
group status of the parent study. Genomic DNA was collected from each participant
using the Orange-DNA Self Collection Kit and processed according to laboratory
protocol from Orange-DNA. Each individual participant was genotyped for BDNF
(rs6265), COMT (rs4680), and APOE( ApoE2, ApoE3, ApoE4). Individual genotype
group analysis was also performed. These particular groups consisted of BDNF genotype
group-Val homozygotes, Valheterozygotes, or Met homozygotes; COMT- Val
homozygotes, Val heterozygotes, or Met homozygotes; and APOE- E2/E3, E2/E4,
E3/E#, E3/E4, or E4/E4. The genetic score risk was computed by summing up the
presence or absence of each genotype. A "0" was assigned for each genotype with
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minimally associated genetic risks with cognitive deficits or a "1" for acknowledged
association with cognitive deficits. A risk score was summarized from these threecomponent risk genotypes. The sum with genetic risk values scored between 0 and 3 was
assigned. The value of "0", the absence of any genetic risk genotypes represent the
lowest genetic risk category for the decline of cognitive status; "1" represents testing
positive for one risk genotype, "2" represents the positive test for two risk genotypes, and
"3" represents possession of all three risk genotypes. The number "3" is also
representative of the highest genetic risk category for the decline in cognitive status.

Demographic variables, such as age, gender, and years of education, were also included
in this analysis.
Analysis of the collected data determined that the hypothesis was statistically
supported. Hierarchical logistic regression analyses were used to determine if any of the
three genotypes were individually predictive of cognitive status. A genetic risk score was
created to represent the accumulation of risk genotypes, such as BDNF, COMT, And
APOE. The demographic variates were used to isolate the effects of the genotypes and to
test whether the risk score predicted the presence of late-life cognitive impairment. The
conclusions were, after controlling variations from age, gender, and education, the APOE
carrier status was predictive of an increased risk of cognitive impairment (OR=3.561,
P=0.032, and 95% CI=1.116,11.365). Neither BDNF or COMT genotype was related to
cognitive status (BDNF, OR=1.149, P=0.755, 95% CI=0.479, 2.759; COMT OR= 1.074,
P=0.808, and 95% CI=0.606, 1.903). The results were consistent with the hypothesis; the
higher the genetic risk score significantly predicted, the higher the risk of having
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cognitive impairment. The study proved a nearly 4-fold increase of cognitive impairment
for sample participants with increased genetic risk scores and individual gene
polymorphisms as covariates (OR=3.824, P=0.013). These findings support the use of a
single genetic risk score to represent the accumulation of genetic influences affecting
cognitive and brain health concerning Alzheimer's disease.
The study is relevant to the current research study for several reasons. The
effectiveness of genetic risk scores and the potential to use these scores as predictors in
cognitive impairment and Alzheimer’s disease will help providers to identify and refer

individuals who are at risk. The current study will help determine if the utilization of
genetic testing is being provided in the primary care setting for individuals with increased
risk for Alzheimer's disease. The ability to provide improved risk assessments to
individuals based on the presence of one or more multiple genotypes will aid in diagnosis
and potentially clarify risks for the patient and family members affected by the disease.
Nola Pender's Health Promotion Model will help guide the current study based on the
theory's concept and emphasis on health promotion. This model can be a crucial
influence for primary care providers in utilizing genetic testing for individuals and the
family members of those who are at increased risk for Alzheimer's disease.
Shinya Tasaki, Chris Gaiteri, Vladislav A. Petyuk, Katherine D. Blizinsky, Philip
L. De Jager, Aron S. Buchman & David A. Bennett conducted a research study to access
genetic influence on motor impairment through a case study of older adults and
established critical molecular pathways that could mediate the risk. The study was
motivated by the increasing evidence of Alzheimer's disease, which impacted late-life in
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both cognitive and motor functions. Genetic variation was claimed to have a significant
impact on the development of Alzheimer's dementia as well as declined cognitive. The
data examined for this study were brain multi-omics, including DNA methylation,
transcriptome, histone acetylation (H3K9AC), and targeted proteomics and diverse
neuropathology. The source of the data for this research, as stated, was gathered from a
total of 552 aged individuals who had at least four out of five omics measurements from
DLPFC. No specific theoretical framework was adopted for this study. Research
questions and hypotheses for the study are identified. The questions that were formulated

in this research were: What is the genetic risk for Alzheimer's dementia influenced motor
functions in older adults? What are the biologic factors linking the genetic risk for
developing Alzheimer's dementia with motor impairment molecules and brain
pathologies explaining most genetic effects? The researchers sought to establish the
relationships between genetic risk variants for AD and motor functioning in older adults.
This study was carried out in the Rush Alzheimer's Disease Center (RADC) in
Chicago and employed two longitudinal, community-based aging studies that contained
various harmonized data measures, which are collectively termed as ROSMAP. The
ongoing studies that the research targeted the older population shows that there is a high
genetic risk for AD variants and motor functioning. The researchers employed a sample
of more than 3,600 older persons who agreed to annual brain donation evaluation as well
as motor testing. A total of 1885 participants completed the genotyping and motor
assessments by March 2018. A certified board of neuropathologists reviewed and
approved the brain autopsies. The study excluded individuals who had cognitive
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impairments but without dementia. Several parameters included motor functions,
Parkinsonism score, motor score, neuropathology indices, omics measures, and PRS. On
the motor assessment function, two related phenotypes validated in previous studies and
without correlation were examined. The global Parkinsonism signs were estimated
within a score of 0 to 100 across each domain. Neuropathology indices were also taken
and described in supplementary methods and a complete list of brain pathologies
assessed. Omics measurements for 7,159,943 single-nucleotide polymorphisms in 2093
subjects were evaluated. Lastly, the PRS generation of variants was identified based on

genome-wide association study data from IGAP and GWAS. The dependent variable
was the Alzheimer's dementia motor deficits, while the independent was the genetic
factors assessed by the researchers. As stated in the study, “the statistical analyses done
involved linear or logistic regression models for testing the association for continuous or
categorical outcomes, respectively.” Demographic variables were dropped with the use
of a linear model, leaving residuals for use in establishing the association. The residuals
were left to test the association at age, sex, years of education, and the first three
genotyping principal genotyping components (PCs), giving an account for possible
stratification within the population. Other analyses were bioinformatic analyses for
evaluation of the AD-PRS effect on motor function. The analysis showed that there were
associations within global Parkinsonism and global motor scores when AD-PRS was
based on IGAP at an SNP threshold of p<0.5. PD-PRSs was also calculated to examine
whether the genetic risk for PD explained variances of motor dysfunction in older adults.
In this study, they did not correlate with motor scores but moderate with Parkinson's
37
disease. The overall results implied that Alzheimer’s disease influenced motor functions
in older adults meaning that cognitive and motor impairment share at least a part in the
genetic architecture. Testing for possible biological factors connecting to genetic risk for
Alzheimer’s disease with motor impairment showed that brain pathologies explain most
of the genetic effects. The results for this study are useful to the bodies identified by the
researchers in that they will be employed in gauging whether they corresponded to those
of past studies in the same area. Further suggestions from this study are to establish
whether there are genes responsible for impairment lying outside of genes supported by

genome-wide significant loci. Various factors that are assessed through the use of
multiple research tools make this study beneficial to the current research. The research
provides a strong basis for building research as it allows for an in-depth insight into how
the research was conducted. The study shared evidence that the evidence of Alzheimer's
disease caused impacts in late-life in both cognitive and motor functions. Genetic
variation was proven to have a significant effect on the development of Alzheimer's
dementia as well as declined cognitive function. This finding can prove to be valuable
information for the current study to assess the genetic influence on motor impairment in
older adults. Yokoyama, Bonham, Sears, Klein, Karydas, Kramer, Miller, and Coppola
conducted a study to determine the reliability of an assessment that observed multivariant heritable probability on a group of phenotypically heterogeneous individuals with
a current Alzheimer's disease diagnosis. This research study was conducted based on
population growth and the medical advances that have allowed individuals to live longer
lives. However, as the population ages, the incidence of Alzheimer's disease increases.
38
Because of the increase in Alzheimer's diagnoses, identifying the individuals at most
significant risk for the development of this neurodegenerative disease is imperative. The
researchers divided Alzheimer's disease into two categories: the patients who present
with amnestic clinical findings and the patients who present with atypical clinical results.
Those with amnestic syndromes will present with common findings of progressive
memory loss and cognitive impairment. The individuals with atypical clinical outcomes
will present with posterior cortical atrophy that affects visual processing, primary
aphasia that affects repetition of words and sentences, and dysexecutive/behavioral

symptoms that affects the emotional and reasoning ability of the individual. Due to the
variation of the disease process, determining genetic variants has proven difficult for
genetic analysis. However, it is estimated that the heritability of Alzheimer's disease is
around 74%, with the e4 allele of apolipoprotein E (APOE) being the most significant
risk factor of the potential diagnosis. This information inspired the researchers to view
the disease from a multi-locus approach in order to "increase the ability to identify
individuals at highest risk for Alzheimer's disease syndrome." The investigation that took
place in this research study involved two approaches to determine the polygenic risk or
probability of the presence of heterogeneous Alzheimer's disease. One approach created
and reviewed the credibility to predict Alzheimer's disease through the use of a multimarker genomic risk score. A discovery associate study had the purpose of reproducing
previous findings related to the disease and observing other variations associated with the
risk of disease in participants. The second approach used a decision tree analysis that
presented the variables and relations between the variables to calculate the result. This
39
calculation allowed them to determine demographic risk factors and hereditary risk
factors that could lead to the development of Alzheimer's disease. The researchers
sought to determine the factors and the interactions between variables that allowed them
to make an educated prediction on individuals who will develop Alzheimer's disease.
Because other research studies determined the APOE genetic marker was the primary
genetic contributor of the disease, the research studies sought to confirm or deny this
finding and determine other significant genetic markers as well.

This research study is a quantitative, quasi-experimental study. The dependent
variable in this study was identified as the participants of the research study, while the
independent variable was the genetic analysis. It was conducted through the first
selecting participants. The individuals ranged from 65-101 years old and agreed to be
subject to genotype analysis. The individuals evaluated could not be related and were
made up of Caucasian males (n=216) and females (n=232). Informed consent was
received from all participants, and approval was granted from the UCSF Institutional
Review Board. The participants then underwent a clinical assessment and were evaluated
through a neurological exam, a cognitive assessment, and assessment of any medical
history. Participants in this study had a partner, such as a friend, spouse, or child that was
assessed to determine functional capabilities and was their source of support throughout
the study. The team consisting of a neurologist, neuropsychologist, and a nurse
established diagnoses through referring to "consensus criteria for Alzheimer's disease."
Atypical Alzheimer's disease diagnoses were also determined, such as logopenic variant
PPA, PCA syndrome, primary executive Alzheimer's disease, vascular disease, and
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dementia with Lewy bodies. Controls in this study were identified as the Mini-Mental
State score of at least 26 or scoring of 0 on the Clinical Dementia Rating Scale. Controls
also included the participants to have no report of the decline of cognition within the
previous year and could not have shown evidence of a neurodegenerative disorder when
observed by the neurological team. If any of these was observed, then the individuals
were excluded from the study.

DNA samples were extracted from the participants through a peripheral blood
sample. These samples were genotyped along with 75 variants to determine the
association with an increased risk of Alzheimer's disease. The 75 variants were
determined through observation of previous research studies used to assess the utility of
genes involved in "neurodegenerative disease, neurodevelopment, social function,
behavior, neuropsychiatry, language on diseases like Alzheimer's disease and
frontotemporal dementia.” The risk scoring was ranked by p-value. The singlenucleotide genetic variations were removed where the alleles presented with the nonrandom linked association. The unlinked markers were used to create a scoring set. This
scoring set algorithm was implemented using a valid genotype/phenotype analysis toolset
to determine its predictability. This process was done to determine both the discovery
and validation cohorts. The decision tree analysis was then determined using stopping
rules. These included "when subgroup totals were less than 10, when a significance
value corresponding to a multiple-testing corrected x^2 test greater than p=0.01 was
reached, or when a three-way interaction was reached." These results allowed for the
analysis of control groups and all participants. There was also an analysis of control
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groups compared with atypical Alzheimer's disease and separately with amnesic
Alzheimer's disease. Added predictors consisted of gender, age, and all genetic variants
with random association alleles. These predictors allowed for genetic variations to be
determined and linked to the development of Alzheimer's disease.
Outcomes of the study determined that the best predictor of Alzheimer's disease
was found by repeatedly generating variants until a risk score panel was developed that

was composed of 17 of those variants. When the APOE genetic marker for Alzheimer's
disease was evaluated independently; it did not reveal a significant prediction value when
compared with the controls. However, in the discovery cohort, the 17-marker risk score
identified the clinical significance of the AUC genotype. It concluded that this marker
was superior to determine the genetic susceptibility of AD than the APOE alone. In the
validation cohort, this did not provide the same outcomes. In this cohort, there were no
other genetic variants that determined susceptibility better than the APOE genetic marker.
When analyzing all cases of Alzheimer's disease among the participants, being a carrier
of the APOE genetic marker was the "first differentiator of cases from controls." Other
predictions of genetic risk were determined to be greater than or equal to 77 years old,
being a carrier for any of the minor alleles, and being homozygous for the dominant
allele, ATP2C2, that controls language traits, such as dyslexia. Because this model used
these predicting factors, it was able to diagnose Alzheimer's disease 87% of the time
correctly. This study determined that the APOE genotype was the superior predictor of
Alzheimer's disease. It also suggested that "phenotype variability in the disease
complicates simple genetic risk modeling, particularly when co-morbidities are
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suspected," meaning those with atypical Alzheimer's disease were more challenging to
predict. However, other studies have been conducted to suggest that atypical Alzheimer’s
disease is more heritable than amnesic Alzheimer’s disease. The researchers
recommended a whole-genome association study in the future with more varied
participants with specific atypical phenotypes. This study could determine differently
genetic susceptibilities specific to Alzheimer’s disease. They also suggested, "phenotypic

specificity in studies of amnestic Alzheimer’s disease may also provide statistical power
to identify risk factors of small effect size.”
This research study is beneficial in the APRN students’ research project on
Alzheimer’s’ disease and genetic testing. It allows for a more genetic viewpoint on the
idea of genetic testing for Alzheimer’s disease.There are so many variations of genetic
make-up concerning this disease that it is imperative to determine which of these variants
will provide the most reliable outcome of an individual's genetic risk. This research
study delves into the scientific side of genetic testing and displays the probability of
which genetic marker best determines the development of Alzheimer’s disease. In
determining the specific variation of Alzheimer's disease, whether atypical or amnestic, a
physician can determine which genetic testing should be done. APOE genotype is the
best predictor of risk for genetic susceptibility among individuals; however, considering
the variation of the disease process, amnestic and atypical Alzheimer’s disease can have
“differential genetic risk factors which can account inaccuracy of the traditional
polygenic scoring method.” Determining those at highest risk of the disease through
being informed on the specific type or variants of genetic markers can allow earlier i
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identification and intervention. This data creates the opportunity to provide clinical
understanding and provide support before the development of symptoms of Alzheimer’s
disease.
A detailed review of literature specific to research related to Alzheimer's disease
and genetic screening serves the current study well as a guide to promoting the need for
further research in this area. The proven research from these studies can be used to direct

strategies to help improve the quality of life for individuals and their families who are or
will be affected by Alzheimer’s disease. Primary emphasis on health promotion that
includes extending longevity, enhancing the quality of life, and reducing health care cost.
The current study addresses these issues, with a focus on determining if genetic screening
is being provided in the primary care setting for those with increased risks of Alzheimer's
disease. Identification and early detection of Alzheimer's disease provide the opportunity
for genetic screening that can provide patients and their families the opportunity to
receive effective management, treatment, and support.

CHAPTER III
Introduction
Because of the increased occurrence of Alzheimer’s disease within the United
States, the researchers sought to determine if the utilization of genetic testing was being
provided in the primary care setting for individuals with increased age, family history,
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical
inactivity, low education, and specific genetic markers (APOE-e4). These factors place

patients at an increased risk for developing Alzheimer's disease. Because Alzheimer's
disease carries such a strong genetic correlation, the researchers hoped to bring awareness
to the importance of genetic testing and encourage providers to consider the avenue of
genetic testing in their practice in order to allow for preparation and health promotion
among the at-risk population. The researchers sought to determine if genetic testing was
being conducted by primary health care providers throughout the state of Mississippi.
Design of the Study
A quantitative survey was used as the design in this study, and was appropriate
for the study to determine if primary care providers were utilizing genetic testing on
individuals with an increased risk of developing Alzheimer’s disease based on
Alzheimer's Association guidelines. Alzheimer’s Association guidelines determine risk
factors for the disease to include not only age and family history, but also diabetes,
hypertension, obesity, smoking, depression, cognitive inactivity, physical inactivity, low
education, and certain genetic markers (APOEe4).
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Setting of the Study
The survey was sent electronically to clinics of various settings across the state of
Mississippi. These various settings included primary care clinics, urgent care clinics, and
specialty clinics. Primary care providers of different credentials were displayed,
including Doctors of Medicine, Doctors of Osteopathic Medicine, Nurse Practitioners, or
Physician Assistants. The participants were selected at random and represented both

urban and rural areas of the state of Mississippi. The survey was also shared on a private
Facebook group of Mississippi Advanced Practice Registered Nurses consisting of 1,700
members.
Population and Sample
A convenience sample was utilized for this study. The population of the study
included men and women of all ages that presented with increased risk factors for
developing Alzheimer’s disease based on the guidelines put forth by the Alzheimer’s
Association. This population was relevant to the study in that age alone does not define
the risk for the development of this disease. Alzheimer’s Association guidelines state
risk factors for the disease include increased age, family history, diabetes, hypertension,
obesity, smoking, depression, cognitive inactivity, physical inactivity, low education, and
certain genetic markers (APOE-e4). Because of the active genetic link related to
Alzheimer's disease, individuals with a family history of the disease are at an increased
risk of exhibiting symptoms of Alzheimer's disease at some point in their life. This
survey determined if genetic screening was being offered to these individuals by their
primary care providers. This information allowed education opportunities for providers
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and promoted the maintenance of cognitive health for maximum longevity among
patients. Electronic surveys were sent out to varying primary care providers through a
reputable survey building website.
Methods of Data Collection
After obtaining consent from Mississippi University for Women's Institutional
Review Board, the researchers distributed surveys with face validity to primary care

providers across the state of Mississippi. The researchers created a survey using a
reliable survey building website, Survey Monkey, Inc. (see Appendix B). These surveys
served as data collection tools and assisted in determining if providers were able to
recognize those at risk for developing Alzheimer's disease based on the Alzheimer's
Association guidelines. The survey also asked questions to determine if those at risk
were being educated and offered genetic screening. The survey began by stating the
intent of the survey and obtaining the consent to participate. It followed with a statement
of privacy, ensuring that no information regarding participants or affiliated clinics would
be revealed. The survey was used to collect demographic data to determine the
credentials of the primary care provider (nurse practitioner, physician’s assistant, or
medical doctor) and their specified area of employment. It followed with questions to
determine if primary care providers were assessing the patient for risk factors that would
place them at an increased risk of developing Alzheimer's disease. It then determined if
genetic screening was being offered to the individuals that were at an increased risk.
These surveys were sent electronically to primary care providers across the state of
Mississippi. The survey was also shared on a private Facebook group of Mississippi
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Advanced Practice Registered Nurses consisting of 1,700 members. The surveys did not
reveal any protected health information or have any patient identifiers. There were also
no participant identifiers as not to skew the research study.
Methods of Data Analysis
Upon completion, data collected was deciphered, evaluated, and compiled. The website,
Survey Monkey, Inc., initially compiled the data. The data was then released to a

reputable statistician who analyzed and parsed the data using chi-square tests to
determine significance. The results were transferred and displayed using varied forms of
charts and graphs. All data and research results were shared with the Mississippi
Alzheimer's Association research group in hopes of educating providers on the
importance of genetic screening for this disease.
Instrumentation
The electronic survey was completed using Survey Monkey, Inc., a reliable survey
building website. It compiled all the data and preserved it securely until the collection
process was completed. The survey consisted of a series of questions developed by the
researchers. Questions included demographic data, provider assessments, evidence
regarding genetic screening being offered, specific cognitive assessment utilized, reasons
genetic screening was not utilized, and the selection of follow-up care provided. The
questions were answered by each provider participating in the survey. The surveys were
sent electronically to various primary health care providers across the state of Mississippi
to determine whether genetic screening was being offered to individuals considered atrisk for developing Alzheimer's disease.
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The survey consisted of multiple-choice questions, with three of those being
“select all that apply” questions. The survey began by stating a right to privacy and
ensuring that no information regarding participants or affiliated clinics would be revealed
through participation in this survey. Questions 1 and 2 determined the demographic data,
including the credentials of the primary health care provider (Doctor of Medicine, Doctor
of Osteopathic Medicine, Nurse Practitioner, or Physician Assistant) and the type of

clinic of affiliation (primary care, urgent care, or specialty clinic). Questions 3 and 4
were related to the research questions and determined if providers were aware of
Alzheimer’s related risk factors and if they were routinely assessing these risk factors.
Question 5 and 6 determined whether the provider was utilizing cognitive testing for
patients at risk for cognitive impairment and specified which cognitive tests were being
conducted, such as the Mini-Mental State Exam (MMSE), the Mini-Cog test, the General
Practitioner Assessment of Cognition test (GPCOG), or other cognitive tests. Question 7
determined if the provider was aware of the research regarding genetic screening for
Alzheimer’s disease. Question 8 was related to the research questions and determined if
genetic screening was being offered or utilized in individuals at an increased risk for
developing Alzheimer’s disease. Question 9 was a “select all that apply” question and
provided the reason genetic screening was not utilized, including time constraints,
insurance coverage, or patient refusal. Lastly, question 10 was a “select all that apply”
question and assisted in determining provider follow up plan of care which included
neurology referral, social services consult, medication for dementia, and/or genetic
counseling. Those who chose to participate in this study had their answers submitted
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anonymously, and the data was compiled, evaluated, and analyzed to determine the
significance of the research study.
Protection of Human Subjects
The study was performed once permission was granted from the Institutional Review
Board of Mississippi University for Women. Human Subjects were utilized in the
conduction of this study through the completion of a survey questionnaire. The survey

determined if genetic screening was being offered to at-risk individuals by primary care
providers throughout the state of Mississippi. Strict caution was taken to maintain
participant privacy and anonymity as data was being collected. No identifying indicators
were revealed, including the participant name or affiliated clinic name. The researchers
utilized a reliable, non-traceable survey building website, Survey Monkey, Inc. The data
collected was stored in a secure location until analyzed and destroyed once the analysis
was concluded. Once the account on Survey Monkey, Inc. was deactivated, all obtained
data information was also destroyed. This policy can be located on the Survey Monkey,
Inc. website. The data obtained was only used for this research project and was not
shared with any affiliated or non-affiliated persons or organizations.
Summary
In conclusion, the researchers hoped to provide education on the importance of genetic
screening in individuals identified with an increased risk of developing Alzheimer’s
disease. This research was conducted through surveys distributed across the state of
Mississippi to primary health care providers. This allowed the researchers to gather data
and determine if individuals were being evaluated and assessed to determine the presence
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of risk factors that placed them at a higher risk of developing Alzheimer’s disease. It also
allowed the researchers to determine if genetic screening was being offered to those atrisk individuals and identified the most common reasons why genetic screening was not
offered. Identifying these individuals and promoting genetic screening will allow for
yearly follow up, genetic counseling, early detection of cognitive decline, and early
intervention.

CHAPTER IV
Presentation of Findings
Alzheimer’s disease is a progressive neurological illness that affects thousands of
individuals every year. The problem was determining whether genetic screening was
being fully utilized in the primary care setting for patients that exhibit increased risk
factors which include increased age, family history, diabetes, hypertension, obesity,
smoking, depression, cognitive inactivity, physical inactivity, low education, specific

genetic markers (APOE-e4) that predispose individuals to Alzheimer’s disease.
Identifying individuals with increased risk factors is essential because early intervention
could provide a solution to controlling this disease and providing statistics for future
research. The purpose of this study was to determine if genetic screening was being
utilized in the primary care setting for individuals who are at increased risk for
developing Alzheimer’s disease. The study sought to determine if signs of Alzheimer’s
disease were recognized quickly in the primary care setting. Surveys were distributed to
various primary health care providers across the state of Mississippi to determine whether
genetic screening was being offered to individuals considered at-risk for developing
Alzheimer's disease. The researchers created a survey using a reliable survey building
website, Survey Monkey, Inc. (see Appendix B). These surveys served as data collection
tools and assisted in determining if providers were able to recognize those at risk for
developing Alzheimer's disease based on the Alzheimer's Association guidelines, and if
those patients were being offered genetic screening. The data was collected from the
surveys and entered in an Excel document. Information obtained from this study will be
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used to help primary providers identify and promote awareness of the signs and risk
factors of Alzheimer’s disease in their patients.
Participant Characteristics
Data for the study were obtained from Survey Monkey, Inc. a reliable survey
building website. The research tool was distributed via social media professional groups

that targeted primary care providers, physician assistants, nurse practitioners, and
physicians. The survey was made available to hundreds of health care providers across
the state of Mississippi. The sample respondents included 20 participants. Of the 20
participants, 18 participants indicated they were nurse practitioners. The other 2
respondents indicated that they were either a family nurse practitioner or a nurse
practitioner student.
Findings
The study concluded with a summation of findings that identified if patients with
increased risk for Alzheimer’s disease were being identified in the primary care setting
and if primary care providers are utilizing genetic screening for high risk patients for
Alzheimer’s disease. The research tool provided included ten questions. The questions
consisted of type of care provider, area of practice, awareness of risk factors, how often
did the provider assess for risk factors, utilization of cognitive testing, tests used, reasons
for not utilizing genetic screening, and what follow up plan of care was used for patients
exhibited signs of Alzheimer’s disease.
When reviewing the data of the study population, the title of care provider was
assessed first (See Figure 1). Of the 20 participants, 90% of the care providers indicated
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that they were nurse practitioners (n=18) and 10% indicated they were either a family
nurse practitioner or a nurse practitioner student (n=2). The next question asked the
participant what his or her area of practice was; 65% (n=13) responded that they were in
primary practice, 20% in primary care (n=4), and 15% (n=3) indicated that they practiced
in another setting, which included the emergency room, nursing homes, and inpatient

behavioral health & addiction (See Figure 2). Of the 20 participants, 80% (n=16)
responded that they were aware of the risk factors that predispose patients to developing
Alzheimer’s disease, whereas 20% (n=4) said that they were not aware of these risk
factors (See Figure 3). The next question asked the care provider if they routinely
assessed or risk factors for Alzheimer’s disease. The survey showed that 70% of the
respondents (n=14) indicated that they routinely assessed risk factors for Alzheimer’s
disease (age, family history, diabetes, hypertension, obesity, smoking, depression,
cognitive inactivity, physical inactivity, and low education) and 30% (n=6) said they do
not (See Figure 4). When asked if the care provider utilized cognitive testing for
individuals with increased risk for cognitive impairment or Alzheimer’s disease, most
respondents (70% (n=14)) indicated they utilize cognitive testing for individuals with
increased risk for cognitive impairment or Alzheimer’s disease and 30% (n=6) said that
they do not utilize cognitive testing (See Figure 5). The next question asked participants
what tests they utilized for testing individuals with increased risk of Alzheimer’s disease .
Most respondents (65%; N=13) indicated using the MMSE for cognitive testing, either
alone or in combination with GDS. The percentage of providers who used the MiniMental State Exam (MMSE) test was 50% (n=10), the Mini-Mental State Exam +
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Geriatric Depression Scale (MMSE + GDS) test was 15% (n=3), the Cambridge
Cognition Exam (CAMCOG) test was 5% (n=1), and No Test Used was 30% (n=6) (See
Figure 6). Only 50% of the respondents (n=10) were aware of research regarding genetic
screening and Alzheimer’s disease, and none of the respondents used genetic screening
for individuals with increased risk for Alzheimer’s disease. Providers were then asked for

reasons for not utilizing genetic screening for individuals with increased risk for
Alzheimer’s disease. Those citing insurance coverage concerns were 45% (n=9),
insurance coverage + time restraints 20% (n=4), patient refusal 5% (n=1), time restraint
concerns 10% (n=2), and other reasons 20% (n=4) (See Figure 7). The most common
reason for not utilizing genetic screening for individuals with increased risk for
Alzheimer’s disease was Insurance Coverage, 65% (n=13). Of the respondents citing
insurance coverage as the reason for not utilizing genetic screening, 4 respondents also
cited time restraints. Time restraints was the second leading reason cited for not using
genetic screening 30% (n=6). Respondents citing other reasons included: 1 being
unaware of genetic testing and 3 indicating their area of practice was the reason
(Emergency Room, Orthopedics, and 1 did not specify). The respondents next indicated
that if the patient screening determined risk factors that predispose the patient to
Alzheimer’s disease, the follow up plan of care would include the following and all that
would apply. Follow up plan of care reported was neurology at 65% (n=13), education
related to Alzheimer’s disease and plan of care at 45% (n=9), medication therapy at 40%
(n=8), lifestyle modification at 30% (n=6), social services consult at 20% (n=4), genetic
screening/counseling at 10% (n=2), and Alzheimer’s support group at 10% (n=2). Most
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(70%) respondents selected more than one item from the follow up plans of care list.
Below is a bar graph that summarizes the actual plans of care indicated by respondents
(See Figure 8). The final question asked providers if the patient screening determines
risk factors that predispose the patient to developing Alzheimer’s disease, as well as what
his or her follow up plan of care would include. The responses were the following: none

indicated at 10% (n=2), neurology referral at 20% (n=4), social services consult at 5%
(n=1), education related to Alzheimer's disease and plan of care (education) at 5% (n=1),
neurology referral + medication therapy at 5% (n=1), neurology referral + medication
therapy + education at 10% (n=2), neurology referral + medication therapy + lifestyle
modification at 5% (n=1), social services + medication therapy + lifestyle modification at
5% (n=1), medication therapy + support group + education at 5% (n=1), genetic
screening + education + lifestyle modification at 5% (n=1), neurology referral +
education + genetic screening at 5% (n=1), neurology referral + education + support
group at 5% (n=1), neurology referral + education + social services consult at 5% (n=1),
neurology referral + lifestyle modification at 5% (n=1), neurology referral + education +
lifestyle modification at 5% (n=1) (See Figure 9).
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Figure 1, Primary Care Providers

Figure 2, Area of Practice
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Figure 3, Aware of Risk Factors

Figure 4, Routinely Assess
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Figure 5, Utilize Cognitive Testing

Figure 6, Cognitive Test Utilized
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Figure 7, Reasons for Not Utilizing Genetic Screening

Figure 8, Follow Up Plan of Care
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Figure 9, Risk Factors Follow Up

Statistical Findings
The purpose of this study was to determine if genetic screening was being utilized in the
primary care setting for individuals who are at increased risk for developing Alzheimer’s
disease. The research study produced 20 respondents in this sample. Eighteen of the 20
participants (90%) identified as being Nurse Practitioners. The other two respondents indicated
that they were Family Nurse Practitioners or Nurse Practitioner students. When respondents
indicated their area of practice, 65% (N=13) responded that they were in primary practice, 20%
in primary care (N=4), and 15% (N=3) indicated that they practiced in another setting, which
included the ER, Nursing homes, and Inpatient Behavioral Health & Addiction.
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Figure 10, Patients at High Risk Being Identified
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Research Question 2
Are primary care providers utilizing genetic screening for patients who are at
increased risk of developing Alzheimer's disease? The answer to this question, based on
this sample of respondents is no. None of the 13 primary care providers utilized genetic
screening for individuals with increased risk for Alzheimer’s disease.

Reasons for not utilizing genetic screening for individuals with increased risk for
Alzheimer's disease
Vali
d

Insurance Coverage
Time Restraints
Patient Refusal
Insurance Coverage + Time
Restraints
Other- Unaware of test
Total

Frequency
6
1
1
4

Percen
t
46.2
7.7
7.7
30.8

Valid
Percent
46.2
7.7
7.7
30.8

Cumulative
Percent
46.2
53.8
61.5
92.4

1
13

7.7
100.0

7.7
100.0

100.0

Table 1. patient or provider time restraints 38.5% (n=5) (See Table 1 & Figure 11).
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Figure 11, Reasons for Not Utilizing Genetic Screening

Summary
In total, 20 surveys were collected from participants across the state of
Mississippi. The research study addressed the research questions set for this study. It
was sought to determine if genetic screening was being utilized in the primary care
setting for individuals who are at increased risk for developing Alzheimer's disease. The
study revealed that primary care providers are aware of patients that exhibit signs for high
risk of developing Alzheimer’s disease. The second research question was also
addressed when respondents were asked if they were utilizing genetic screening for those
with increased risks of Alzheimer’s disease. Only 50% of the respondents (N=10)
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acknowledged they were aware of the research regarding genetic screening and the
disease. There was no data collected that confirmed genetic screening was being offered
or utilized for this population.

CHAPTER V
Summary and Conclusions
Alzheimer's disease is an irreversible, progressive disease of the brain that slowly
begins with the destruction of memory and cognition and eventually leads to the inability
to perform necessary activities of daily living. This disorder of the brain is a substantial
health problem and the disease occurrence is increasing with the aging population.
Unfortunately, there is no standard screening protocol for the diagnosis and progression
of the disease. It is the sixth leading cause of death in the United States, accounting for
almost 4% of all deaths in 2014 (CDC, 2017). Current disease management focuses on
preserving memory and cognition and managing behavioral symptoms. The researchers
sought to determine if providers in the primary care setting were identifying
individuals/patients at increased risk of developing Alzheimer's. Factors that increased
the risk of Alzheimer’s disease was defined to include advanced age, family history,
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical
inactivity, and low education. The researchers also sought to determine if primary care
providers were offering and utilizing genetic screening for those individuals/patients who
were identified with positive risk factors for developing Alzheimer’s. The researchers
used Nola Pender’s Health Promotion Model (HPM) as the theoretical framework to
guide this study.
After reviewing the literature associated with this ongoing health problem, it was
revealed by numerous studies that early testing of patients with a family history or other
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predispositions to the disease, such as hypertension or diabetes, could invoke lifestyle
changes that could modify the progression of the disease. The researchers determined that
early intervention could be a substantial component in controlling this disease by
identifying patients in primary care who are at high risk for developing Alzheimer's
before the clinical onset of the disease, and those with positive risk factors. These genetic
variations can later be further identified and aid providers with definitive diagnosis and
interpretation of risk for those individuals and their families.
The e4 allele of apolipoprotein E (APOE) gene poses the most substantial risk
concerning the development of the disease. It is included in many of the clinical trials and
research studies discussed in the review of literature, such as Tasaki et al., where the
study determined that the APOE genotype was the superior predictor of Alzheimer's
disease. Along with this, Yokoyama et al. also reiterated the strong genetic correlation to
Alzheimer’s disease and further supported the APOE genotype as being the most
significant risk factor of the potential diagnosis. In this research study patients underwent
cognitive testing prior to genetic testing and had to score at least a 26 on the Mini-Mental
State Exam score or a 0 on the Clinical Dementia Rating Scale. Genetic testing was then
done to test for the APOE gene, and the patients were followed closely with weekly
cognitive testing to investigate mental decline. This research provided improved risk
assessments on individuals based on the presence of the APOE genotype aided them in
diagnosis and potentially clarifying risks for the patient and family members affected by
the disease. The current research project sought to exemplify the strong genetic
correlation in the review of literature in order to support the importance of genetic t
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testing. While this importance was conveyed, there were no primary care providers
within the current research study that stated the utilization of genetic testing. Evanson et
al. actually found in the research study that physicians expressed immense knowledge of
genetic testing but lower levels of confidence about communicating that knowledge with
their patients. The current research study did determine lack of knowledge of genetic
testing related to Alzheimer’s disease as a reason genetic testing was not performed or
offered. Along with this, the study by Brodaty et al. revealed time investment as a
significant limitation in providing cognitive screening to the elderly. This was also true in
the current research study performed. A large portion of responses expressed time
constraints as a reason for not utilizing or performing genetic testing on individuals at
risk for developing Alzheimer’s disease.
In this study, the researchers used a quantitative survey as the design for data
collection. Strict caution was taken once approval was granted by the Institutional
Review Board at Mississippi University for Women to ensure participant privacy and
anonymity as data was collected. The researchers provided questions in the survey using
SurveyMonkey, Inc. This survey included demographic data, the determination of
provider assessments, the evidence of genetic screening offered, the cognitive
assessments used, the reason genetic screening was not utilized, and the follow-up care
provided for those who chose genetic screening. The sample size was 20. Upon
completion of the data collection, the researchers determined that genetic testing was not
being utilized by primary care providers in the state of Mississippi. The summary and
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discussion of the findings along with implications, limitations, and recommendations will
be discussed for the remainder of the chapter.
Interpretation of Findings and Conclusions
The purpose of this study was to determine if genetic screening was being utilized
in the primary care setting for individuals at increased risk of developing Alzheimer's
disease. The researchers had 20 respondents in this sample. Eighteen of the 20
participants (90%) identified as being Nurse Practitioners. The other two respondents
indicated that they were Family Nurse Practitioners or Nurse Practitioner students. When
respondents indicated their area of practice, 65% (N=13) responded that they were in
primary practice, 20% in primary care (N=4), and 15% (N=3) indicated that they
practiced in another setting, which included the ER, nursing homes, and inpatient
behavioral health & addiction. When the respondents were asked if they were aware of
genetic screening for Alzheimer’s disease, only 50% of the respondents (N=10)
acknowledged they were aware of the research regarding genetic screening and
Alzheimer’s disease. When questioned if the risk factors of Alzheimer’s disease were
routinely assessed, including age, family history, diabetes, hypertension, obesity,
smoking, depression, cognitive inactivity, physical inactivity, and low education, 70% of
the respondents (N=14) indicated that they did routinely assess for these risk factors. The
participants were questioned if they utilized cognitive testing for individuals with
increased risk for cognitive impairment or Alzheimer’s disease, and most of the
respondents (70%, N=14) indicated that they did utilize cognitive testing routinely. Of the
respondents who utilized cognitive testing, (65%; N=13), the Mini-Mental State Exam
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(MMSE) was selected as the primary assessment for cognitive testing. The respondents
replied that they utilized the MMSE either alone or in combination with the Geriatric
Depression Scale. When the research question was asked to determine whether genetic
screening was offered or utilized in patients with an increased risk of developing
Alzheimer's, none of the respondents stated utilization of genetic screening for
individuals with increased risk for Alzheimer’s disease. When questioned about the
reasoning of not utilizing genetic testing, the respondents 65% (N=13) indicated
insurance coverage prevented them from offering genetic testing. Of the respondents
stating insurance coverage as a reason not to utilize genetic screening, four respondents
also stated time restraints as a limitation. Time restraints were the second leading reason
cited for not using genetic screening (30%; N=6). Four respondents cited other reasons
genetic testing was not utilized, including one respondent unaware of genetic testing, and
three respondents in an area of practice where it was not considered applicable (ER,
Orthopedics, and one did not specify). According to the results of this survey, patients
who are at increased risk of developing Alzheimer's disease are being identified and
screened. Thirteen of the respondents work in a primary care setting. Of these, 76.9%
(N=10) routinely assessed risk factors for Alzheimer's disease. Of those who routinely
assessed risk factors of Alzheimer's disease, eighty percent (N=10) utilized cognitive
testing for these individuals at increased risk for developing Alzheimer's Disease. Genetic
testing was not being offered or utilized within the primary care setting to individuals at
risk for developing Alzheimer’s. While most primary care providers were identifying and
screening these individuals at increased risk for developing Alzheimer's, none of the 13
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primary care providers who participated in the survey offered or utilized genetic
screening for these identified individuals. Of the 13 primary care providers identified, the
key reasons chosen for not utilizing genetic screening was lack of insurance coverage
(76.9%; N=10) and patient/provider time restraints (38.5%; N=5). To determine the
follow up plan of care once risk factors had been identified,, the respondents were
provided with a question in the format of selecting all that apply. The following options
were listed: neurology referral, social services consult, education related to Alzheimer’s
and plan of care, lifestyle modifications, genetic counseling, and medication therapy.
Seventy percent of respondents selected a combination of the listed options. Two of the
respondents selected that they would not include any of the options in the at-risk patient’s
follow-up plan of care. Four respondents (20%) selected a neurology referral alone, while
one respondent (5%) selected only a social services consult. One respondent (5%) opted
to utilize only education regarding Alzheimer's disease. Two respondents (10%) selected
a combination of medication therapy, education regarding Alzheimer’s disease, and
neurology referral as their preferred follow-up plan of care. One respondent (5%)
selected a neurology referral and medication as a desired plan of care while another
respondent (5%) selected neurology referral, medication therapy, in addition to lifestyle
modifications. One respondent (5%) chose to utilize social services, medication, and
lifestyle modifications, while another respondent (5%) relied on medication, genetic
counseling, and education regarding the disease process. Another respondent (5%)
selected genetic screening, medication, and lifestyle modifications, while a separate
respondent (5%) utilized genetic screening and medication but preferred genetic
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counseling over lifestyle modifications. Another (5%) respondent opted for a neurology
referral, education regarding respondent Alzheimer's, and lifestyle modifications while
another respondent (5%) only selected a neurology referral and education. The final
respondent (5%) selected a neurology referral and a social service consult regarding the
treatment plan of care of an individual identified as at increased risk of developing
Alzheimer's. Overall, 13 of the 20 respondents selected either alone or in combination to
refer to their patient identified to be at an increased risk of developing Alzheimer's to
neurology for management of the disease process. While none of the survey participants
offered or utilized genetic screening to individuals at risk for developing Alzheimer’s,
two of the respondents did include genetic screening along with a combination of other
options in their proposed plan of care.
There were two research questions addressed in this study. Are patients at
increased risk for developing Alzheimer's disease being identified by providers in the
primary care setting; and are primary care providers utilizing genetic screening for
patients at increased risk for developing Alzheimer's disease? When reviewing the
current practices for screening patients of patients with increased risk, seventy-nine
percent of providers routinely assessed risk factors for Alzheimer's disease. Eighty
percent of the respondents identified as utilizing cognitive testing. None of the
respondents offered genetic testing for the patients at increased risk for developing
Alzheimer's. This study highlighted the lack of genetic testing as being utilized.

74

The findings of the current researchers were similar to those of Brodaty et al. in that both
studies suggest that cognitive testing is beneficial for a timely diagnosis of Alzheimer's
disease.
Limitations
The limitations of the study which were identified prior to data collection were
only a small geographical area was studied, a small sample size being collected, and
limited distribution of the study was distributed via social media outlets to distribute to
the appropriate audience, this limitation only included feedback from Nurse Practitioners
which limited access to gather and collect data. The research questions only addressed
primary care providers, neglecting those that work in specialty areas such as neurology,
and psychology that are also capable of utilizing genetic testing, thereby limiting the
range of responses. The reliability of survey data was also considered a limitation not due
to the respondents providing accurate honest answers. Lack of confidence in the subject
area could also limit the study to biased responses.
The major limitation on the research study was a global pandemic. COVID-19
created numerous limitations in health care and prevented researchers from hands on
collection of data. Alzheimer's disease is the most common cause of dementia. This
disease occurs worldwide and affects all ethnic groups. The findings concluded in this
study were that patients who are at increased risk of developing Alzheimer's disease are
being identified and screened, and over half of the respondents identified as routinely
assessing risk factors. Those who regularly evaluate risk factors (80%) utilize cognitive
testing for the individuals at increased risk. Only 50% of the respondents (N=10) were
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aware of research regarding genetic screening. The researchers concluded that none of
the respondents used or offered genetic screening for individuals with increased risk for
Alzheimer's disease. The primary reason for not using or offering genetic screening for
individuals with increased risk for Alzheimer’s disease as insurance coverage.
Implications and Recommendations
It is estimated by 2050, 16 million people will be diagnosed with Alzheimer's
(CDC, 2017). It is the sixth leading cause of death in the United States (CDC,2017).
Modifiable risk factors such as diet, and cognitive challenges have been shown to slow
the disease process (CDC, 2017). Medical management can improve the quality of life
for individuals living with Alzheimer’s disease and their caregivers. There is currently
no known cure for Alzheimer’s disease. In order to provide education on modifiable risk
factors, the providers must be aware and up to date on genetic screenings.
Our research project revealed that although Primary Care Providers in Mississippi
are aware of the availability of genetic screening, very few are utilizing genetic testing
for patients with increased risk for Alzheimer's disease. The most common reason for not
implementing genetic screening for their patients with risk factors for Alzheimer's was
insurance coverage, followed by time restraints. This study implies that even though the
awareness is there, the resources are not utilized. With the results of this research study,
providers can explore opportunities to implement better screening and utilization of
existing resources into their practices. This survey was specifically designed to test the
knowledge and utilization of the available testing for patients at an increased risk of
developing Alzheimer's. With early knowledge, the primary care provider could
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implement lifestyle changes that could prolong the patient's quality of life. The nursing
theory used in this study shows that a patient will do better if they know to do so.
Increasing knowledge not only increases awareness for the patient but the provider, as
well.
Recommendations that arise from the results of this research study include
increasing awareness of the benefits of genetic testing for patients with increased risk of
developing Alzheimer's Disease as well as increasing the sample size and the
geographical area. Mass marketing on Social media and television could encourage
patients to start asking questions about their care, and the options they have. When
patients are included in their plan of care, they are better to adhere to treatment options,
and make those lifestyle changes to prevent or slow the progression of developing the
disease. Future research could expand their sample size by doing paper surveys, as well
as face to face interviews to obtain feedback. Educating Primary Care Providers and the
public would increase the demand for such testing. Education plays a significant factor in
the lack of use of any resource. Education on the benefits of early intervention for those
at-risk patients, for their families, as well as the Primary Care Provider, would also
increase the usage of this resource. Recommendations for Advanced Nursing Practice is
the implementation of a guideline for screening would be beneficial. For example, in the
electronic medical record (EMR), there could be screening questions that target cognitive
decline. There could be standardized steps to implement in the early stages of decline.
More focus on family history should be a talking point with the patient. Family history
could be a reliable indicator of the need for early detection by genetic screening.
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Insurance Coverage was the most common factor that prevented the utilization of genetic
screening. If providers utilize genetic testing more frequently, insurance companies will
begin to include it in their covered benefits. Also, lobby for insurance coverage for
genetic screening as a preventative service to decrease the patient's rate of decline, which,
in turn, reduces insurance pay-out.
Recommendation for future research can be done to assess the provider willingness to
utilize genetic testing if education was more readily available, and insurance coverage
was not an issue. If all of the stated barriers were removed, what would be the patient's
increased benefit? Would their quality of life be improved? Would the patient change
anything about their lifestyle? Would mental health be more of a priority in the routine
care of patients? These questions could be the starting points for future discussions.
Summary
This study was conducted to provide education on the importance of genetic
screening in individuals identified with an increased risk of developing Alzheimer’s
disease. The study was conducted through a quantitative survey distributed to health care
providers across the state of Mississippi. This allowed researchers to gather data and
determine if individuals who were at increased risk of developing Alzheimer’s disease
were being identified and offered genetic screening. While the study revealed most
primary care providers were identifying and screening these individuals who were at
increased risk for developing Alzheimer's, none of the providers that participated in the
survey offered or utilized genetic screening for these identified individuals. The study
also provided insight to the most common reasons why genetic screening was not offered,
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which was found to be time constraints and insurance coverage. Studies have been
conducted to prove the identification of individuals with increased risks of Alzheimer’s
disease and the promotion of genetic screening in the primary care setting would allow
for yearly follow up, genetic counseling, early detection of cognitive decline, and early
intervention. There are many limitations to this study that can be improved upon and
corrected for future research. This study provides a substantial foundation and realization
that although risk factors are being identified in the primary care setting, genetic
screening is not being offered. Utilization of this data, along with further research will be
beneficial to promote the importance of early intervention for those at risk of Alzheimer’s
disease.
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Appendix B

Survey
Instructions to participants are as follows:
● By completing this survey, you are giving consent to participate.
● This survey is both a demographic and data collection survey to determine if
genetic testing is utilized in the primary care setting for individuals with an
increased risk of Alzheimer's disease.
● Participants will remain anonymous.
● No participant shall identify their employment facility.

Please select the most appropriate answer to the following questions:
1. Please select which best applies.
A. Doctor of Medicine (M.D.)
B. Doctor of Osteopathic Medicine (D.O.)
C. Nurse Practitioner
D. Physician’s Assistant
E. Other:_________________________

2. Please select which best describes your area of practice.
A. Primary Care Clinic
B. Urgent Care Clinic
C. Specialty Care Clinic / Other:____________________

3. Are you aware of the risk factors that predispose patients to Alzheimer’s
disease?
A. Yes
B. No
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4. Do you routinely assess risk factors for Alzheimer’s Disease (age, family history,
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity,
physical inactivity, and low education) in your clinical practice?
A. Yes
B. No

5. Do you utilize cognitive testing for individuals with increased risk for cognitive
impairment or Alzheimer’s disease?
A. Yes
B. No

6. If yes, which cognitive test is utilized?
A. MMSE
B. CAMCOG
C. GPCOG
D. Geriatric Depression Scale (GDS)
E. Other

7. Are you aware of research regarding genetic screening and Alzheimer’s Disease?
A. Yes
B. No

8. Do you offer/ utilize genetic screening for individuals with increased risk for
Alzheimer’s Disease?
A. Yes
B. No
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9. If no, what are your reasons for not utilizing genetic screening for individuals
with increased risk for Alzheimer's disease? Select all that apply.
A. Insurance coverage/ Cost to patient
B. Time restraints
C. Patient refusal

10. If the patient screening determines risk factors that predispose to Alzheimer's
disease, does your follow up plan of care include: Select all that apply.
1. Neurology referral
2. Social services consult
3. Medication for dementia
4. Genetic screening/counseling
5. Alzheimer’s support group
6. Education related to Alzheimer’s disease and treatment.

APPENDIX C

Descriptive Statistics
There were 20 respondents in this sample. Eighteen of the 20 participants (90%)
indicated being Nurse Practitioners. The other two respondents indicated that they were
FNP or NP students.
Professional title
Valid

Nurse Practitioner
FNP/NP Student
Total

Frequency
18
2
20

Percent
90.0
10.0
100.0

Valid Percent
90.0
10.0
100.0

Cumulative
Percent
90.0
100.0

When indicated the area of practice, 65% (N=13)responded that they were in Primary
practice, 20% in primary care (N=4), and 15% (N=3) indicated that they practiced in
another setting, which included the ER, Nursing homes, and Inpatient Behavioral Health
& Addiction.
Are you aware of the risk factors that predispose patients to developing
Alzheimer's disease?
Valid

No
Yes
Total

Frequency
4
16
20

Percent
20.0
80.0
100.0

Valid Percent
20.0
80.0
100.0

Cumulative Percent
20.0
100.0

70% of the respondents (N=14) indicated that they routinely assessed risk factors for
Alzheimer’s disease (age, family history, diabetes, hypertension, obesity, smoking,
depression, cognitive inactivity, physical inactivity, and low education)
Do you routinely assess risk factors for Alzheimer’s disease (age, family
history, diabetes, hypertension, obesity, smoking, depression, cognitive
inactivity, physical inactivity, and low education) in your clinical practice?
Valid

No
Yes
Total

Frequency
6
14
20

Percent
30.0
70.0
100.0

Valid Percent
30.0
70.0
100.0

Cumulative Percent
30.0
100.0
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Again, most of the respondents (70%, N=14)) indicated that they utilize cognitive testing
for individuals with increased risk for cognitive impairment or Alzheimer’s disease.
Do you utilize cognitive testing for individuals with increased risk for
cognitive impairment or Alzheimer’s disease?
Valid

No
Yes
Total

Frequency
6
14
20

Percent
30.0
70.0
100.0

Valid Percent
30.0
70.0
100.0

Cumulative Percent
30.0
100.0

Most respondents (65%; N=13) indicated using the MMSE for cognitive testing, either
alone or in combination with GDS.
Test utilized
Valid

No test used
MMSE
MMSE + GDS
CAMCOG
Total

Frequency
6
10
3
1
20

Percent
30.0
50.0
15.0
5.0
100.0

Valid Percent
30.0
50.0
15.0
5.0
100.0

Cumulative Percent
30.0
80.0
95.0
100.0

Only 50% of the respondents (N=10) were aware of research regarding genetic screening
and Alzheimer’s disease, and none of the respondents used genetic screening for
individuals with increased risk for Alzheimer’s disease.
The most common reason for not utilizing genetic screening for individuals with
increased risk for Alzheimer’s disease was Insurance Coverage, 65% (N=13) of
respondents indicating that this was a reason. Of the respondents citing insurance
coverage as a reason not to utilize genetic screening, four respondents also cited time
restraints. Time restraints was the second leading reason cited for not using genetic
screening (30%; N=6). Four respondents cited other reasons, including one being
unaware of genetic testing and three indicated their area of practice (ER, Orthopedics,
one did not specify).
Reasons for not utilizing genetic screening for individuals with increased
risk for Alzheimer's disease
Valid

Insurance Coverage
Time Restraints
Patient Refusal
Insurance Coverage + Time
Restraints
Other
Total

Frequency
9
2
1
4

Percent
45.0
10.0
5.0
20.0

Valid Percent
45.0
10.0
5.0
20.0

Cumulative
Percent
45.0
55.0
60.0
80.0

4

20.0

20.0

100.0

20

100.0

100.0

The respondents indicated that if the patient screening determine risk factors that
predispose to Alzheimer’s disease, the follow up plan of care would include the
following:
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Follow up plan of care reported

Frequency

Percentage

Neurology

13

65.0

Education related to Alzheimer’s disease and plan of care

9

45.0

Medication Therapy

8

40.0

Lifestyle modification

6

30.0

Social Services Consult

4

20.0

Genetic Screening/Counseling

2

10.0

Alzheimer’s Support Group

2

10.0

Most (70%) of respondents selected more than one item from the follow up plans of care
list. Below is a table that summarizes the actual plans of care indicated by respondents.
If the patient screening determines risk factors that predispose to
Alzheimer's disease, does your follow up plan of care include:
Valid

None indicated
Neurology referral
Social Services Consult
Education related to
Alzheimer's disease and
plan of care (Education)
Neurology referral +
Medication Therapy
Neurology referral
+Medication Therapy
+Education
Neurology referral +
Medication Therapy +
Lifestyle Modification
Social Services + Medication
Therapy+ Lifestyle
modification
Medication Therapy
+Support Group +Education
Genetic Screening
+Education +Lifestyle
Modification
Neurology Referral
+Education +Genetic
Screening
Neurology Referral +
Education + Support Group
Neurology referral +Social
Services Consult

Frequency
2
4
1
1

Percent
10.0
20.0
5.0
5.0

Valid Percent
10.0
20.0
5.0
5.0

Cumulative
Percent
10.0
30.0
35.0
40.0

1

5.0

5.0

45.0

2

10.0

10.0

55.0

1

5.0

5.0

60.0

1

5.0

5.0

65.0

1

5.0

5.0

70.0

1

5.0

5.0

75.0

1

5.0

5.0

80.0

1

5.0

5.0

85.0

1

5.0

5.0

90.0

Neurology Referral +
Lifestyle modification
Neurology Referral+
Education +Lifestyle
modification
Total

1

5.0

5.0

95.0

1

5.0

5.0

100.0

20

100.0

100.0

Research Questions:
1.
Are patients who are at increased risk of developing Alzheimer's disease being
identified by providers in the primary care setting?
According to the results of this survey, patients who are increased risk of developing
Alzheimer’s disease are being identified and screened. Thirteen of the respondents work
in a primary care setting. Of these, 76.9% (N=10) routinely assess risk factors for
Alzheimer’s disease. Of those that routinely assess risk factors of Alzheimer’s disease,
80% (N=10), utilize cognitive testing for these individuals at increased risk.

2.
Are primary care providers utilizing genetic screening for patients who are at increased
risk of developing Alzheimer's disease?
The answer to this question, based on this sample of respondents is no. None of the 13 primary
care providers offers/utilized genetic screening for individuals with increased risk for
Alzheimer’s disease. For this subset of the sample, the primary reasons given for not using
genetic screening in Insurance Coverage (76.9%; N=10) and Patient/Provider time restraints
(38.5%; N=5).

Reasons for not utilizing genetic screening for individuals with increased
risk for Alzheimer's disease
Valid

Insurance Coverage
Time Restraints
Patient Refusal
Insurance Coverage + Time
Restraints
Other- Unaware of test
Total

Frequency
6
1
1
4

Percent
46.2
7.7
7.7
30.8

Valid Percent
46.2
7.7
7.7
30.8

1
13

7.7
100.0

7.7
100.0

Cumulative
Percent
46.2
53.8
61.5
92.4
100.0
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